Multi-OMICs landscape of SARS-CoV-2-induced host responses in human lung epithelial cells

Sneha M. Pinto, Yashwanth Subbannayya, Hera Kim, ..., Terje Espevik, Denis Kainov, Richard K. Kandasamy

Highlights
- Performed a multi-OMICs analysis to expand the current knowledge on SARS-CoV-2 infections
- Post-translational modifications regulate cell signaling during host antiviral response
- SARS-CoV-2 causes activation of DNA damage response and dysregulation of Hippo signaling
- Exometabolome analysis showed dysregulated cellular metabolism
Multi-OMICs landscape of SARS-CoV-2-induced host responses in human lung epithelial cells

Sneha M. Pinto, Yashwanth Subbannayya, Hera Kim, Lars Hagen, Maria W. Górna, Anni I. Nieminen, Magnar Bjørås, Terje Espevik, Denis Kainov, and Richard K. Kandasamy

SUMMARY
COVID-19 pandemic continues to remain a global health concern owing to the emergence of newer variants. Several multi-Omics studies have produced extensive evidence on host-pathogen interactions and potential therapeutic targets. Nonetheless, an increased understanding of host signaling networks regulated by post-translational modifications and their ensuing effect on the cellular dynamics is critical to expanding the current knowledge on SARS-CoV-2 infections. Through an unbiased transcriptomics, proteomics, acetylomics, phosphoproteomics, and exometabolome analysis of a lung-derived human cell line, we show that SARS-CoV-2 Norway/Trondheim-S15 strain induces time-dependent alterations in the induction of type I IFN response, activation of DNA damage response, dysregulated Hippo signaling, among others. We identified interplay of phosphorylation and acetylation dynamics on host proteins and its effect on the altered release of metabolites, especially organic acids and ketone bodies. Together, our findings serve as a resource of potential targets that can aid in designing novel host-directed therapeutic strategies.

INTRODUCTION
The rapid emergence of the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still shows no abatement. Despite the availability of several vaccines, the emergence of newer variants with enhanced transmissibility and pathogenesis is a major cause of concern. Current efforts to develop antiviral therapeutics, especially host-directed therapies, are vital to significantly reduce the impact of both the current and future coronavirus epidemics. Several classes of FDA-approved drugs and drugs currently in clinical trials have been repurposed, showing promising results in hospitalized patients with severe diseases.

Development of host-directed therapeutics largely depends on the available information as the viral genome continuously evolves to adapt to the host environment and evade pre- or post-countermeasures. Several host factors that promote or restrict SARS-CoV-2 replication have been identified by genome-wide CRISPR knockout screens. Furthermore, multi-OMICS studies have provided vital insights into understanding the viral profile, mechanisms of pathogenesis, and identifying host factors. Notably, the role of protein post-translational modifications (PTMs), are increasingly recognized as key mechanisms viruses employ to target signaling pathways regulating host immune responses. Nevertheless, strain-specific differences and their effects on the host cellular machinery, especially in evading the immune response and facilitating further transmissibility and clinical manifestations, are only recently being explored.

Given the evolving number of variants, a multi-OMICS approach focusing on the dynamic interplay of PTMs is vital aiding in therapeutics development and is helpful in pandemic preparedness. Most studies have focused on elucidating the phosphorylation dynamics and alterations in ubiquitin and glycosylation. Some are restricted to characterizing the glycosylation patterns of virus/membrane proteins. Emerging evidence highlights protein lysine acetylation as a key regulatory mechanism originally thought to modulate epiproteome. Epigenetic responses are now increasingly identified as promising therapeutic targets in human viral infections. However, alterations in global host acetylation dynamics
and the dynamic interplay with other PTMs in mediating viral pathogenesis in response to SARS-CoV-2 infection remain to be explored. Furthermore, the effect of the altered signaling dynamics on the metabolite profile and, in turn, its impact on cellular interactions on infection is yet to be determined. Increasing evidence shows that in addition to altering levels of intracellular metabolites, viral infections can result in the altered release of metabolites into the extracellular milieu. Quantitative measurements of exometabolites or metabolic footprinting enable the determination of metabolic state, serving as a reporter of the cellular physiology. Given the vital significance of cell-cell interactions and the control of its microenvironment, it is important to characterize the exometabolome changes on SARS-CoV-2 infection.

Here we present a quantitative survey of the alterations in the global transcriptome, proteome, phosphorylation, lysine acetylation and exometabolite dynamics of SARS-CoV-2 Norway/Trondheim-S15 strain infected Calu-3 human lung epithelial cells. We map the altered changes to disrupted kinases and signaling pathways affecting cellular response to infection and cell survival. Overall, our findings demonstrate the control of host machinery by SARS-CoV-2 through PTM modulation.

RESULTS AND DISCUSSION
Quantitative temporal viromics analysis of SARS-CoV-2 infection

Host responses to SARS-CoV-2 infection were investigated using a multipronged approach comprising transcriptomics, TMT-based quantitative temporal proteomics, phosphoproteomics, acetylmics, and targeted exometabolomics analysis. The analysis was performed on human lung epithelial Calu-3 cells infected with a clinical isolate of SARS-CoV-2 (hCoV-19/Norway/Trondheim-S15/2020 strain) at a multiplicity of infection (MOI) of 0.1 at five-time points including 3, 6, 12, 24, and 48 hours post-infection (hpi) (Figure 1A). We chose this MOI as a productive viral infection, and increased cytopathic effects were observed 72 hours post-infection in a previous study that used the same viral strain. Robust changes in transcript abundance and protein PTM dynamics were observed compared to protein abundance changes, and the findings are in concordance with previous reports. Similarity matrices based on the Spearman correlation coefficient demonstrate a high correlation across most datasets at the transcriptome (Figure S1A) and proteome levels (Figure S1B). Across the datasets, 17,663 transcripts, 6,080 proteins, 24,013 phosphorylated peptides mapping to 5,487 phosphoproteins, 1,503 acetylated peptides mapping to 662 acetylated proteins, and 85 targeted metabolites were identified and quantified. A total of 3,457 transcripts, 216 proteins, 4,497 phosphopeptides mapping to 2,157 phosphoproteins, and 112 acetylated peptides mapping to 90 proteins, respectively, were found to be differentially regulated across all time points (fold change cutoff log2 \( \geq -1.5 \) or \( -0.5 \) for transcriptome and \( \geq 0.5 \) or \( -0.5 \) for other datasets) (Figure 1B, Tables S1–S4).

In addition, increased expression of viral genes at both the transcript and protein levels, as well as altered phosphorylation and acetylation levels in 7 viral proteins (acetylation observed only on nucleoprotein), was observed. Our data demonstrated a strong correlation between the time points and biological replicates post-data filtering and quality control analysis (Figures S1C–S1F). The extent of differential regulation of host and viral proteins was minimal in contrast to the marked hyperphosphorylation observed at earlier time points of infection. Contrarily, the acetylmic dynamics revealed a profound downregulation as early as 6 hpi, indicative of viral-induced PTM-specific regulatory mechanisms. Overall, enrichment of antiviral and innate immune signaling pathways and regulation of DNA damage response and cell cycle processes were observed across the different levels (Figure 1C). A minimal overlap across the differentially expressed transcript/protein/phosphoprotein/acetyl protein levels across all time points indicates discreet molecular-level regulation (Figure 1D). The multi-omics data is available as a queriable database “SARS-CoV-2 map” (http://sarscov2map.org/, Figure 1E)

GLOBAL PROTEOME AND TRANSCRIPTOME ANALYSIS REVEAL INDUCTION OF INNATE IMMUNE RESPONSE

Analysis of the global gene expression dynamics revealed a similar extent of gene regulation at early time points (3, 6, and 12 hpi), albeit with a slight increase in the number of downregulated genes at 12 hpi. Several genes were overexpressed at later time points of infection. Akin to transcriptome changes, host cellular proteins were significantly downregulated, especially 12 hpi (Figure 2A, Tables S1 and S2). Our
Figure 1. Multi-omics analysis of SARS-CoV-2 infected Calu-3 cells

(A) Experimental workflow for the proteomic and phosphoproteomic analysis of Calu-3 cells infected with SARS-CoV-2/Trondheim-S15/2020 strain.

(B) Barplots summarizing the number of differentially regulated transcripts, proteins, phosphopeptides, acetylpeptides, and secreted metabolites identified in Calu-3 cells infected with SARS-CoV-2.
Notably, CMPK2, an immunomodulatory ISG associated with antiviral responses in immune cells, were induced as early as 12 hpi with the overexpression of antiviral factors, and interferon-stimulated genes and a kinase involved in mtDNA synthesis and DNA repair, was upregulated at 24 and 48 hpi both at time points of infection (3–12 hpi), whereas the rest were upregulated at later time points (24–48 hpi) (Figure 1C). Specifically, interferons-IFNB1 (Type I IFN) and IFNL1, -2, -3, -4 (Type III IFN) were induced as early as 12 hpi with the overexpression of antiviral factors, and interferon-stimulated genes (ISGs) such as OAS1-3, IFIT1-3, IFITM at both transcriptomes and proteome levels (Figures 2B and 2C). Notably, CMPK2, an immunomodulatory ISG associated with antiviral responses in immune cells, and a kinase involved in mtDNA synthesis and DNA repair, was upregulated at 24 and 48 hpi both at transcriptome and proteome levels. Using immunoblot analysis, we confirmed the induction of OAS1, ISG15, TRIM5α, RNase-L, MX1, and CMPK2. (Figure 2D). Comparing the ISG expression profile with that of the early lineages and Alpha variant revealed a similar extent of expression in the Trondheim strain and Alpha variant compared to the early lineage viruses (IC19 and VIC), indicating strain-specific differences in inducing interferon response (Figure 2E).

Although it is well established that Interferons activate Toll-like receptor (TLR) gene expression in macrophages during viral infections, including in SARS-CoV-2, the expression of TLR genes in response to viral infections in epithelial cells is less known. Several members of the TLR family, including TLR1 (24 and 48 hpi), TLR3 (24 and 48 hpi), TLR4 (6 and 24 hpi), and TLR6 (24 and 48 hpi), were found to be upregulated in the Calu-3 transcriptome in response to infection. TLR2 has been reported to sense the SARS-CoV-2 envelope protein and thereby produce inflammatory cytokines, causing inflammation and damage in the lungs. Although we did not identify differential expression of TLR2, increased expression of TLR1 and TLR6, known to form heterodimers with TLR2, was observed. Notably, TLR3 activation has been reported in SARS-CoV-2-infected Calu-3 lung epithelial cells, whereas there is indirect evidence indicating the involvement of TLR4 in epithelial cells during SARS-CoV-2 infection. Concerning the expression of the pro-inflammatory cytokine signature (TNF, IL1B, IL6, CCL2, CXCL9, CXCL10, CXCL11) previously shown to be upregulated in plasma and/or BAL of severe COVID-19 patients, overexpression of IL1B was observed at early time points of infection (3–12 hpi), whereas the rest were upregulated at later time points (24–48 hpi) (Figure 2C). However, analysis of the cell supernatants indicated a time-dependent increase in CXCL10, VEGF, and GDF15 (MIC-1) levels, with no secretion of other pro-inflammatory cytokines. (Figures 2F and S2D). Overall, our findings concord with previous studies indicating that Calu-3 cells respond to SARS-CoV-2 infection and induce an antiviral response, albeit to a varying extent compared to other strains.

**SARS-CoV-2 mediated modulation of PTM dynamics affects key host signaling pathways contributing to viral pathogenesis**

To assess the impact of SARS-CoV-2 infection on host cellular signaling dynamics, serial enrichment analysis of phosphorylation and lysine acetylation was performed. Supervised clustering revealed 8 distinct clusters corresponding to early (clusters 5 and 6), intermediate (cluster 6), late (hyperphosphorylated: clusters 1, 7, and 8; hypophosphorylated: cluster 2), and sustained responses (clusters 3 and 4) (Figure 3A). A minimal overlap was observed when comparing the hyperphosphorylated sites identified in the current study with other studies on the SARS-CoV-2 phosphoproteome (Figure 3A). Given the differences in the cell types, strains and platforms, it is not surprising that a large majority of sites identified vary across studies. Nevertheless, pathway analysis revealed enrichment of cytokine signaling, activation of DNA damage and repair pathways, Hippo signaling, cell cycle regulation, RNA splicing, and regulation of translation and transcription across different clusters indicative of viral-mediated alterations of host cellular machinery (Figure 3B, Table S5).

Notably, differential phosphorylation of proteins related to the antiviral immune response (Cluster 1), including increased phosphorylation of STAT1 and STAT3 at S727 12 hpi, was observed with sustained levels seen even at 48 hpi (Figure 3A). Immunoblot analysis further validated our findings (Figure 3D). Phosphorylation and activation of STAT1/3 are required for the complete transcriptional activity of the ISGF
Inhibition of MEK functionally restored the activity of ROCK1/Rho-kinase in promoting cytoskeleton reorganization. It has been previously shown that sustained RAF/MAPK signaling results in the downregulation of ROCK1, which is required for stress fiber formation and promote cytoskeleton reorganization of cellular processes.

Cluster 2 revealed significant enrichment of time-dependent decrease in phosphorylation of proteins involved mainly in the regulation of cell cycle processes, DNA damage and repair pathways and chromatin modification such as CDK1, CDK2 (T14, Y15), CDK4/6, DNA topoisomerases (TOP2A (S1106, S1213, S1504), TOP2B (T1431) and transcription factors/co-regulators- RB1, APC, TP53). Enrichment of DNA damage response pathway at the early time point corroborates with an earlier study that reported that infectious bronchitis virus (IBV) activated ATR-dependent cellular DNA damage response to induce cell-cycle arrest for the enhancement of viral replication and progeny production. They further demonstrated that the interaction between Coronavirus nsp13 and DNA polymerase δ was essential for the induction of DNA damage response and cell-cycle arrest at the S phase. Responses enriched as early as 3hpi indicate enrichment of protein autophosphorylation required for activation of kinases modulating downstream cellular processes.

It has been previously shown that sustained RAF/MAPK signaling results in the downregulation of ROCK1 and Rho-kinase, two-Rho effectors required for stress fiber formation and promote cytoskeleton reorganization. Inhibition of MEK functionally restored the activity of ROCK1/Rho-kinase in promoting cytoskeleton reorganization in NRK/RAS cells. We observed sustained MAPK1 activation on SARS-CoV-2 infection with decreased levels of pROCK1 24 hpi, thereby suggesting potential alterations in cytoskeleton organization (cluster 4). Increased phosphoERK1/2 (T202, Y204) was confirmed by immunoblotting (Figure 3D).

Further discussed in subsequent sections.

We also observed temporal changes in the SARS-CoV-2-responsive kinome and phosphatome (Figure 3C), with several protein kinases demonstrating decreased phosphorylation levels over time. On the contrary, the phosphorylation levels of protein phosphatases such as PTPN3, CTDSPL, and CTDSPL2 increased with time, with 9 phosphatases hyperphosphorylated at 24 hpi. Of the 107 kinases found to be differentially regulated, 18 have been described as substrates of viral proteins, including kinases involved in PI3K/akt signaling (GSK3β, RAF1, PAK4), cell cycle (PRKDC, CDK2, and TTK) and MARK kinase signaling (MARK2 and MARK3). Further PTM signature enrichment analysis using PTMSigDB revealed enrichment of signatures of MAPK signaling pathways including MAPK14, MAPKAP2, leptin pathway, PRKACA, cell cycle kinases CDK1, CDK2, and Aurora B at early time points of infection correlating with activation of DNA damage and repair pathways and altered cell cycle regulation (Figure S3B). Furthermore, a substantial number of transcription factors were differentially phosphorylated in response to SARS-CoV-2 infection.
Multiple sites. In addition to proteins enriched in glucose/hexose metabolism, Cluster 3 consisted of hypoacetylation and hexose biosynthetic process, as well as histone subunits (H2B and H4C), acetylated on lysine K26 and K39 decreased at 6 hpi with the proteome expression downregulated 24 hpi. In contrast, the protein expression was downregulated only at 48 hpi. On the contrary, the acetylation levels of TMSB4X at K26 and K39 decreased at 6 hpi with the proteome expression downregulated 24 hpi. k-means clustering of the acetylome measurements enabled the segregation of the regulated genes into early, late, and mid-late responders to viral infection. We largely observed significant downregulation of protein abundance changes except for CDK1 (K33), which was found to be hypoacetylated at 24 hpi. In contrast, the protein expression was downregulated only at 48 hpi. On the contrary, the acetylation levels of TMSB4X at K26 and K39 decreased at 6 hpi with the proteome expression downregulated 24 hpi.

Pathway enrichment analysis largely revealed the enrichment of proteins involved in various biological processes (Figure 3F). Notably, a time-dependent decrease in the acetylation levels across proteins belonging to several classes but primarily histones, epigenetic modifiers, and proteins involved in metabolic regulation. Cluster 1, which largely showed a delayed response, was enriched in proteins involved in glucose metabolism and hexose biosynthetic process, as well as histone subunits (H2B and H4C), acetylated on multiple sites. In addition to proteins enriched in glucose/hexose metabolism, Cluster 3 consisted of hypoacetylated proteins involved in the regulation of the mitochondrial organization. Acetylation of GAPDH at K251 was observed as early as 3 hpi, followed by a persistent decline at later time points of infection. Acetylation at this site is known to be mediated by PCAF and is required for nuclear translocation of GAPDH during apoptotic stress.81 In the case of other metabolic enzymes, a progressive decline in the acetylation status was observed across time points, with a significant reduction post 24 h. Cluster 2 and Cluster 4 were enriched in proteins involved in viral transcription and translation termination, further corroborating the role of viruses inducing host protein translation shutoff activity. In addition, proteins localized to the membrane were enriched in Cluster 4, whereas proteins involved in macromolecule complex disassembly and translational elongation were enriched in Cluster 2. Acetylation of EIF5A2, a translation initiation factor essential for cell growth at K47, is responsible for regulating its subcellular localization with the hypoacetylated form predominantly localized to the cytoplasm.82 Cluster 5 includes histones-H2AZ1 acetylated at K8, K12, and K14, H3C1 (K24), as well as keratins KRT17 (K219) and KRT19 (K215) were found to be hyperacetylated 12 hpi. H3C1 is a core component of the nucleosome and is involved in the process of post-transcriptional and translational regulation of genes. Furthermore, studies have revealed that the site H3C1 (K24) is amenable to acyl modifications and is highly responsive and reversibly regulated by nutrient availability.83 Overall, our data is indicative of SARS-CoV-2 mediated triggering of deacetylases and likely restricted availability of acetate pool that results in significant decrease in protein acetylation at later time points of infection. These results correlate with an earlier report suggesting that active deacetylase activity is required to induce ISG expression and antiviral immune responses,84 thereby creating an environment conducive to increased viral replication.
We next assessed if there was an overlap of dysregulated phosphorylation and acetylation datasets. Our data clearly shows interplay of phosphorylation and acetylation on host proteins. In all, we identified 37 proteins with differentially regulated multiple PTM sites. These include proteins involved in innate immune signaling (PPIA, HSP90AA1, ILF3, ANXA2, ANXA4, and CFL1), regulation of cellular metabolic processes as well as proteins involved in the regulation of mRNA stability, including ANP32A, a multifunctional transcriptional regulator and a component of the inhibitor of histone acetyltransferases complex.85,86 Significant hypoacetylation was observed at 24–48 hpi, with the phosphorylation levels on T15 and S17 showing an opposite trend (Figure 3G). Of interest, the levels of ubiquitination at K99, as demonstrated by Stukalov et al., were downregulated as early as 6 hpi with a minimal increase over time. Host proteins, especially ANP32A, interact with influenza virus RNA polymerase components, forming a replication platform essential to promoting vRNA synthesis.87,88 Furthermore, ANP32A is known to be a component of the inhibitor of histone acetyltransferases complex and modulates the HAT activity of EP300/CREBBP (CREB-binding protein) and EP300/CREBBP-associated factor89,90 and is involved in the positive regulation of ISG transcription85,86 which we observe at both transcript and protein levels. It remains to be determined if the differential acetylation at this site located in the LRR domain plays a role in CoV-2 replication and infectivity. As described previously, we also identified distinct phosphorylation and acetylation patterns on several sites on Vimentin (VIM), an essential host factor responsible for the entry and pathogenesis of SARS-CoV-2.91 Decreased acetylation levels as early as 6 hpi (K294, K402) whereas distinct phosphorylation on several sites early (S73) or late (S83, S325, S420, and S430) were observed (Figure S3E). Of interest, Stukalov et al. report decreased ubiquitination levels following infection with SARS-CoV-2 and SARS-CoV.

A comparison of the changes in the acetylation data with the ubiquitinome performed in ACE2-A549 cells29 revealed 26 proteins common across the datasets. Of these, ribosomal proteins- RPL13A (K159), RPL34 (K36), RPL7 (K29), RPS25 (K57); LLRC59 (K135), and UBE2N (K82) were differentially modified at the same residue. However, the PTM dynamics observed were opposite in trend, especially at 24 hpi, wherein the acetylation levels were downregulated as opposed to increased ubiquitination. Notably, LLRC59, a leucine-rich repeat-containing ER membrane protein, plays an important role in innate immune signaling by modulating DDX58-mediated type I IFN signaling92 and regulating trafficking of nucleic-acid sensing TLRs.93 It was found to be hypoacetylated at 6 hpi with acetylation reaching basal level at 12 hpi. On the contrary, the ubiquitination levels at K135 and others (K71, K207) remain unchanged at 6 hpi but gradually increase across time points, with significantly elevated levels observed at 24 hpi (Figure S3F). Overall, our findings emphasize the need to assess the effects of different post-translational modifications simultaneously, as the functional outcome of the cellular response is dependent on the concerted action of regulatory machinery.

Modulation of secretory effectors involved in SARS-CoV-2 infection

To identify molecular/metabolic pathways perturbed following SARS-CoV-2 exposure, we measured the extent of release of 100 metabolites in the culture supernatants of Calu-3 cells treated with SARS-CoV-2 for the time points described above (Figure 1A). Of these, 85 were identified and quantitated across five time points after SARS-CoV-2 infection and were considered for further analysis. A total of 163 differential events were identified across the five time points, of which 146 were increased, and 17 were decreased (Figure 4A). The metabolites that were significantly changed in response to SARS-CoV-2 infection have been provided in Table S6.

Changes in the metabolite release and metabolic pathway perturbations were analyzed using targeted metabolome-wide association. Metabolite set enrichment analysis (MSEA) indicated significant enrichment of several metabolic pathways, including the TCA cycle, Glycolysis/Gluconeogenesis, butanoate metabolism, and metabolism pathways of several amino acids (Figure 4B). Metabolites involved in amino acid metabolism, including branched-chain amino acids, and aromatic amino acids, were among the significantly enriched pathways at early and mid-time points of infection. At later time points, arginine metabolism and metabolites of the TCA cycle pathways were found to be significantly enriched. However, the extent of changes in the levels of arginine was not significant across the time points. We further compared and correlated our findings from the exometabolome data with intracellular metabolomics studies of SARS-CoV2 mediated dysregulation in cellular metabolism.94,95 Primarily focusing on glycolysis, TCA cycle and amino acid metabolism as it is known that cellular metabolism specifically energy metabolism supports the demand for viral replication.96,97 Using fold-change values to compare metabolite levels, we observed similar increases in extracellular and intracellular levels with respect to glycolysis metabolites. However, only a
The increased secretion of several acids and ketone bodies in response to SARS-CoV-2 indicated that N-acetylneuraminic acid (Neu5Ac) serves as a plausible alternative receptor for SARS-CoV-2. We observed increased levels of sialic acid N-acetylneuraminate as early as 3 hpi, and it has been recently reported demonstrating the role of energy metabolism on viral replication and rewiring of antiviral immune responses. In concordance with earlier reports, over 3-fold induction of viral proteins with similar expression trends across all nine viral proteins were consistently identified and quantified across six time points of infection. In concordance with previous reports, over 3-fold induction of viral proteins with similar expression trends across all nine viral proteins was observed. The dynamics of protein expression across time points indicated that the viral protein synthesis increased continuously post-infection, with a peak observed at 24 hpi except for Orf8, with a slight decrease in expression observed at 48 hpi (Figure 1C, Table S2). SARS-CoV-2 N, M, S, and Orf9b were among the most abundant proteins consistently detected.

Analysis of the PTM dynamics revealed 41 phosphorylation sites on eight viral proteins with maximum changes in the phosphorylation dynamics observed post 12 hpi (Figure 5A). The trend observed was in accordance with the increase in protein abundance. Comparison with previously reported SARS-CoV-2 phosphoproteome enabled us to identify ten novel phosphorylation sites on 6 viral proteins, including ORF1a (S142, S2517) and ORF3a (T24, S272), ORF7a (S44), ORF8 (S103) (Figure 5B). Replicase protein 1a (P0DTC1) is a polyprotein that is proteolytically cleaved to generate several non-structural proteins. We found the polyprotein to be modified on 3 sites; one corresponding to NSP1 (S142) and 2 sites corresponding to NSP3 (S2517, S2644). In concordance with earlier studies, multiple sites of phosphorylation on the viral proteome profile

In addition to the changes in host cellular proteins, analysis of upregulated DEGs revealed a significant increase in the expression of viral genes observed mainly at 24 hpi (Table S7). This was demonstrated by the low alignment rate observed against the human reference database, indicating that the RNA fraction at these time points was taken over by the virus. At the proteome level, nine canonical SARS-CoV-2 proteins were consistently identified and quantified across six time points of infection. In concordance with previous reports, over 3-fold induction of viral proteins with similar expression trends across all nine viral proteins was observed. The dynamics of protein expression across time points indicated that the viral protein synthesis increased continuously post-infection, with a peak observed at 24 hpi except for Orf8, with a slight decrease in expression observed at 48 hpi (Figure 1C, Table S2). SARS-CoV-2 N, M, S, and Orf9b were among the most abundant proteins consistently detected.

Analysis of the PTM dynamics revealed 41 phosphorylation sites on eight viral proteins with maximum changes in the phosphorylation dynamics observed post 12 hpi (Figure 5A). The trend observed was in accordance with the increase in protein abundance. Comparison with previously reported SARS-CoV-2 phosphoproteome enabled us to identify ten novel phosphorylation sites on 6 viral proteins, including ORF1a (S142, S2517) and ORF3a (T24, S272), ORF7a (S44), ORF8 (S103) (Figure 5B). Replicase protein 1a (P0DTC1) is a polyprotein that is proteolytically cleaved to generate several non-structural proteins. We found the polyprotein to be modified on 3 sites; one corresponding to NSP1 (S142) and 2 sites corresponding to NSP3 (S2517, S2644). In concordance with earlier studies, multiple sites of phosphorylation on the viral proteome profile
The nucleocapsid protein, including 3 novel sites corresponding to T245, S327, and S379, clustered in the linker region between the RNA-binding (RBD) and dimerization domains as well as located in the dimerization domain (S327) were observed (Figure 5C). The nucleocapsid protein plays an essential role in the replication, transcription, and assembly of the SARS-CoV-2 genome and is also known to control host cell cycle machinery. The identified phosphorylation motifs were bioinformatically assessed using NetPhos 3.1 to predict potential host kinases phosphorylating the viral proteins (Figure 5D). Consistent with previous findings, we too observed several motifs in nucleoprotein to be modified by CMGC kinases, including members of MAPK family CDKs and GSK3. Of interest, we observed several novel phosphorylation sites (N, ORF1a, ORF8) mapping to recognition motifs of the AGC family-PKA, PKB, and PKC and DNAPK, a critical player involved in the DNA damage response pathways. It is known that DNA-PK acts as a DNA sensor that activates innate immunity. However, its role in phosphorylating RNA virus N protein, especially at the novel site T379 located C-terminal of the dimerization domain, remains to be explored. In concordance with previous results, we also observed an increased phosphorylation level of nucleocapsid protein. A recent study observed the highest percentage of disorder compared to other viral proteins as well as a high number of variable molecular recognition features (MoRFs) and classified as a highly disordered protein with a central role in viral pathogenesis. Furthermore, the viral acetylome profile revealed hyperacetylation of 6 sites on nucleoprotein, including at K65, K248, K249, K256, K341, and K362. Of these, two sites on the nucleoprotein (K248, and K249) have been recently demonstrated to be acetylated by P300/CBP-associated factor (PCAF) and general control nonderepressible 5 (GCNS). The hyperacetylation of N protein coincides with the hypoacetylation of ANP32A and the induction of ISGs, which strongly demonstrates the critical role of ANP32A in modulating the host PTM dynamics, thereby contributing to viral pathogenesis.

We next looked at the positions of phosphorylated residues in the available and predicted structural models of SARS-CoV-2 proteins (Figure 5S). For those residues that could be mapped on the available structures, all the identified phosphorylation sites were plausible because they were located at the surface of the proteins and, therefore, should be accessible to kinases. Similar to the previous reports, most of these residues were located in loops or at the edge of secondary structure elements. The majority of the side chains were not engaged in any intramolecular interactions (for example, S63 of ORF9b or T141 and S327 of N protein), though some residues formed hydrogen bonds that could support the positioning of some flexible loops (for example, S103 of ORF8 or S44 of ORF7a) or contribute to an interaction with another protein (T72 of ORF9b bound to the backbone of V556 of Tom70). In addition, many phosphorylation sites were found in regions that were missing from crystal or cryo-electron microscopy structures and therefore presumed to be likely in unstructured regions (for example, T24, S272, and T248 of ORF3a). Indeed, one such region was S176-S180 of Protein N, which was modeled as a flexible linker in the NMR ensemble and is part of the serine/arginine-rich (SR) domain at the start of one of the predicted intrinsically disordered regions (IDR) (residues 1–44, 175–254, 365–400). The SR region may participate in RNA binding and is a hotspot for mutations in Protein N. Of interest, S327 of N Protein, a phosphorylation site unique to our study, has also been found to be frequently mutated, typically to Leu. For some of the most interesting cases for which experimental models were missing, we used computational modeling with TrRosetta. Although computational models should be approached as only approximate, especially in the positioning of flexible regions and the orientation of independent domains, they all showed that the phosphorylation sites were located on protein surfaces and in flexible regions, including T172, S212, and S213 of Protein M, T24, S272 and T248 of ORF3a, S50 of ORF6, S26, T245 and T379 of Protein N, S142 of Rep1a (Nsp1), S2517 and S2644 of Rep1a (Nsp3). In summary, the phosphorylation sites observed in this study were predicted to be unlikely to play an important structural role in supporting the architecture of SARS-CoV-2 proteins, which corresponded well to their exposed positions and the lack of conservation noted in some cases. Instead, phosphorylation might play a role in regulating interactions mediated by these residues – the change in electrostatic potential or in the pattern of hydrogen bonds could alter the binding of other proteins or RNA. Whether these could be beneficial or detrimental to the SARS-CoV-2 remains to be validated by functional studies.
Integrated analysis of key signaling pathways and processes identified in our datasets using pre-defined gene sets from MSigDB revealed significant changes at multiple levels on proteins involved in Hippo signaling, DNA/damage/response, protein ubiquitination, alternate splicing pathways (Figures 6A–6G and S6A–S6H) and metabolic pathways involved in energy metabolism (Figure S7). Although the phosphoproteome data showed a time-dependent decrease in the phosphorylation status of Hippo signaling, other pathways, including DNA damage/response, protein ubiquitination, and spliceosome pathways, demonstrated increased signaling. The proteome changes showed reduced expression, whereas the transcriptome showed increased transcription of genes belonging to these pathways.

Although in cancers, the Hippo signaling pathway is a tumor suppressor by nature,113 various studies have indicated its crucial role in viral infections such as those caused by Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human papillomavirus (HPV), Epstein-Barr virus (EBV), Zika virus (ZIKV), amongst others.114 During the course of Hippo signaling, MST1/2 kinases (STK3/STK4) phosphorylate and activate Lats1/2 kinases, which in turn phosphorylate and inhibit essential transcriptional coactivators-YAP/TAZ (YAP1/WWTR1).113,115 When upstream kinases are repressed, dephosphorylated YAP/TAZ accumulate in the cell nucleus and associate with several transcriptional factors that stimulate genes involved in cell survival and proliferation, including TEADs, ERBB4, EGR1, TBX5, and members of the SMAD and RUNX family.116 Notably, YAP was found to negatively regulate the antiviral immune responses in Sendai virus (SeV), vesicular stomatitis virus (VSV), and herpes simplex virus type 1 (HSV-1) infections.117 Wang et al. further demonstrated that depletion of YAP in macrophages increased interferon beta expression. Also, YAP overexpression led to repression of IRF3 dimerization through YAP association and decreased nuclear localization of IRF3. Furthermore, viral-mediated activation of IKKε phosphorylated YAP led to its degradation, thereby relieving cells of YAP-mediated antiviral response. We observed altered phosphorylation of Hippo signaling-related proteins in response to SARS-CoV-2 infection. Recently Garcia et al. showed that activation of the Hippo signaling pathway during SARS-CoV-2 infection contributed to host antiviral response.118 Furthermore, using a pharmacological inhibitor of YAP, the infection mediated by SARS-CoV-2 was significantly reduced. This study corroborates our findings on the importance of Hippo signaling in the context of SARS-CoV-2 infection and its regulation of the innate immune response.119 In the current study, we observed hypophosphorylation of upstream kinases involved in Hippo signaling, including STK3 (S386, T354, S370/S371), and STK4 (S40, T41, S43). Furthermore, we observed YAP1 (S61) and WWTR1 (S62, T67) phosphorylation levels progressively decreasing and the lowest at 48 hpi. In addition, validation using immunoblot corroborated the hypophosphorylation of YAP1 at S61. Furthermore, we observed hypophosphorylation of PRKAA1 or AMPK (S486, T490), an upstream kinase that phosphorylates YAP1 at S61.120 We also found other regulators of the Hippo signaling pathway such as KIBRA or WWC1 (S947), FRMD6 (S375), NF2 (S518), and ZO-2 or TJP2 (S966, S1027) to be hypophosphorylated. Signaling crosstalk between the Hippo and TGFβ pathways is known.121 In our study, TGFβ receptor TGBFR2 was progressively hyperphosphorylated, reaching maximal hyperphosphorylation at 48 hpi. LATS-mediated phosphorylation of YAP results in its interaction and binding to 14-3-3, leading to cytoplasmic retention.122 We identified hypoacetylation of both YWHAB (14-3-3β) at K13 and YWHAZ (14-3-3ɛ) at K11. Whether altered acetylation directly affects YAP localization and activity remains to be determined.

Although it is well known that metabolic cues can control YAP/TAZ regulation,124,125 increasing evidence suggests YAP influences cellular metabolism. YAP has been demonstrated as a central regulator of glucose metabolism,126 mediating the regulation of glucose transporter 1 (glut1) in zebrafish. Yap mutant zebrafish were reported to have impaired glucose uptake, nucleotide synthesis and glucose tolerance in adults.127 Our study indicates high levels of glycolysis intermediates, including glucose 6-phosphate, fructose 6-phosphate, dihydroxyacetone phosphate, and lactate at 48 hpi. These findings likely suggest that YAP and, thereby, hippo signaling could profoundly impact glucose metabolism during SARS-CoV-2 infection. We further observed increased alpha-ketoglutarate, proline, and uracil levels in response to SARS-CoV-2 infection and likely associate this observation with dysregulated YAP/Hippo signaling as YAP has been found previously to regulate fatty acid oxidation and amino acid metabolism.128 YAP inhibition in the skeletal muscles decreased levels of various metabolites, including undecanoic acid, capric acid, 2-octanoic acid, 2-oxoglutaric acid (alpha-ketoglutarate), amino acids-lysine, serine, proline, aspartate and uracil intermediate, 3-ureidopropionic acid. YAP has also been shown to regulate glutamine metabolism to stimulate nucleotide biosynthesis through increased expression of glutamine synthetase in zebrafish.129 In light
Ubiquitination is essential in regulating the innate immune response. E3 ligases, such as TRIM25 and RIPLET, have been shown to mediate RIG-I ubiquitination and type I IFN induction. We observed several Ubiquitin (Ub) E2 and E3 ligases such as UBE2C, UBE2J1, UBE2S, PJA2, RNF5, RNF14, and RNF115, among others, to be significantly downregulated as early as 12 hpi with no changes in the total protein levels. We further confirmed our results through immunoblot analysis (Figure 6H). YAP1/Hippo signaling has also been known to cross-talk with the DNA damage response pathways, and this could help explain why DNA damage/repair pathways were enriched in Calu-3 on SARS-CoV-2 infection. Cross talk between YAP and P53 via a SIRT-1 mediated deacetylation mechanism is involved in the control of cell cycle in AS49 lung cells. In addition, TAZ (or WWTR1) has been shown to reduce P53 activity through p300-mediated acetylation negatively. Notably, ANP32E has previously been reported to reduce P53 activity through p300-mediated acetylation negatively. Notably, ANP32E has previously been reported to remove H2A.Z from DNA double-strand breaks, promoting DNA repair and nucleosome organization. All these findings suggest a deeper connection between DNA damage and YAP/TAZ signaling.

Furthermore, the DNA damage response pathway was enriched across multiple omics datasets in response to SARS-CoV-2 infection. We identified p53 S314/315, not S15, and the phosphorylation level was downregulated (log2FC = 0.5). Immunoblot analysis revealed decreased phosphorylation of p53 S15 and corresponded to the reduced abundance of total p53 levels indicating CoV-2 infection potentially mediates p53 degradation (Figure 6H). At later time points of infection, we observed hyperphosphorylation of Ser/Thr kinase PRKDC (also known as DNAPK) at multiple sites. DNAPK acts as a molecular sensor for DNA damage and is also known to regulate DNA virus-mediated innate immune response. We identified hyperphosphorylation of several DNAPK sites including S3205, an ATM target phosphorylated either through autophosphorylation or through PLK1 and S2672, which is part of the ABCDE cluster, which promotes DNA end processing, and autophosphorylation of this cluster is required to initiate DNA damage repair. Regulation of DNA damage response mechanism by DNAPK is mediated by phosphorylation of S139/S140 of histone variant H2AX/H2AFX. Concurrently, we observed increased phosphorylation of γH2AX at S140 from 12 hpi with no changes in the total protein levels. We further confirmed our results through immunoblot analysis (Figure 6H). YAP1/Hippo signaling has also been known to cross-talk with the DNA damage response pathways, and this could help explain why DNA damage/repair pathways were enriched in Calu-3 on SARS-CoV-2 infection. Cross talk between YAP and P53 via a SIRT-1 mediated deacetylation mechanism is involved in the control of cell cycle in AS49 lung cells. In addition, TAZ (or WWTR1) has been shown to reduce P53 activity through p300-mediated acetylation negatively. Notably, ANP32E has previously been reported to remove H2A.Z from DNA double-strand breaks, promoting DNA repair and nucleosome organization. All these findings suggest a deeper connection between DNA damage and YAP/TAZ signaling.

Ubiquitination is essential in regulating the innate immune response. E3 ligases, such as TRIM25 and RIPLET, have been shown to mediate RIG-I ubiquitination and type I IFN induction. We observed several Ubiquitin (Ub) E2 and E3 ligases such as UBE2C, UBE2J1, UBE2S, PJA2, RNF5, RNF14, and RNF115, among others, to be significantly downregulated as early as 12 hpi (Figure 6H). To assess if this affected the status of protein ubiquitination, the pan-Ub profile was explored using Anti-Ub FK2, which detects K29-, K48-, and K63-linked mono- and polyubiquitylated proteins. Similar to the expression profiles of E3 ligases, a significant decrease in ubiquitination was observed, especially at 24 hpi (Figure 6I), suggesting CoV-2-mediated hijacking of the host ubiquitin system to maximize their own survival likely through mechanisms adopted by DNA tumor viruses and Adenoviruses. A recent study aimed to identify substrates of the Mpro from three coronaviruses revealed many E3 ubiquitin ligases were cleaved by the SARS-CoV-2 main protease Mpro including RNF20, ITCH, UBE3A, confirming our findings that albeit increased expression at the transcript level, profound downregulation of E3 ligases owing to degradation was essential to counteract the host innate immune response. In addition, Coronaviruses encode papain-like protease (PLP) that acts as a cysteine protease as well as possesses intrinsic deubiquitinating and deISGylating activities required for viral replication and the evasion of host responses.

We observed time-dependent dephosphorylation of several proteins involved in the cell cycle at multiple sites, including Rb, which acts as a key driver of cell cycle regulation. A time-dependent decrease in phosphorylation at S249, T821, and T826 is known to be mediated by members of type 1 serine/threonine protein phosphatases (PP1) was observed. Earlier studies indicate that endogenous Rb is dephosphorylated on T821 when cells undergo apoptosis. Changes in the phosphorylation dynamics were accompanied by downregulation at the proteome level for most proteins involved in regulating cell cycle processes. (Figure 6J).
In addition to the various cellular processes regulated at multiple levels, changes in the expression dynamics as well as alterations in the phosphorylation/acetylation status of genes involved in energy metabolism specifically glycolysis, TCA cycle and amino acid metabolism was evaluated (Figure S7). We observed extensive transcriptional changes of genes belonging to these pathways, however the impact on the protein expression seemed to be minimal. Notably, altered PTM status indicating hyperphosphorylation and hypoaecetylation especially at later time points of infection of several glycolysis and TCA cycle genes was observed. The altered PTM dynamics correlate with increased viral gene expression signifying their role in the metabolic reprogramming of human airway epithelial cells in response to SARS-CoV-2 infection. However, further studies are warranted to understand the precise role of these post-translational modifications in the regulation of these metabolic pathways.

**Conclusions**

We describe a systems-level approach to discover signaling pathways modulated on infection of Calu-3 cells with SARS-CoV-2 S15 Trondheim strain belonging to the wave 1 isolates. In-depth systems-wide and time-resolved characterization of the host and viral changes throughout productive infection revealed temporal changes in the transcriptome, proteome, phosphoproteome, acetylyome, and exometabolome. Although other studies have extensively explored SARS-CoV-2 mediated alterations in the proteome and phosphoproteome of infected cells, to our knowledge, this study is the first to perform comprehensive profiling, including exploring the acetylyome and exometabolome dynamics in response to SARS-CoV-2 infection. Multiple genes and functional pathways identified in our data were previously reported to promote SARS-CoV-2 mediated pathogenesis, validating the rigor of our approach and providing further support for the role of these specific host factors. In concordance with earlier studies, we too observed a robust induction of the innate immune response accompanied by increased interferon signaling, increased expression of ISGs, TLRs, and cytokines and chemokines. Integrated analysis revealed changes in Hippo signaling, DNA damage response, ubiquitination, and spliceosome machinery pathways across omics datasets. In response to infection, several novel phosphorylations and acetylation sites were identified on vital host proteins. We also provide evidence of host-mediated PTM modification of viral proteins, including time-dependent alterations in the acetylation levels of nucleoprotein for the first time. Altered PTM levels have been demonstrated to influence virus-mediated control of host cellular dynamics and the role of novel acetylation sites warrants further investigations. Altered release of TCA cycle intermediates with increased secretion of organic acids especially lactate strongly indicates enhanced aerobic glycolysis or Warburg-like effect that likely supports SARS-CoV-2 replication in airway epithelial cells. Furthermore, secretion of ketone bodies such as BHB could likely be a counteractive measure to restrict SARS-CoV2 infection. Finally, the data from the study shows evidence of potential crosstalk between Hippo signaling, DNA damage response, glucose metabolism and post-translational modifications. However, the site-specific alterations in the PTM dynamics and its effect on the signaling crosstalks in response to SARS-CoV-2 infection will need to be deciphered in greater detail by future investigations.

Although we observed a small overlap with other in vitro Calu-3 infections studies, a comparison of both the transcriptome and proteome of uninfected Calu-3 cells revealed a high degree of correlation across datasets. Furthermore, differences were also observed with several published multi-omics studies on SARS-COV-2 infection of other cell types. Overall, our findings demonstrate that the variance observed is unlikely because of pronounced expression program differences of uninfected Calu-3 cells rather influenced by protocols used for infection, sample preparation, and data acquisition strategies. Nevertheless, the processes and functional pathways identified in our data have been previously reported to promote SARS-CoV-2-mediated pathogenesis. A detailed compilation of the information would provide a holistic overview on the discreet molecular level regulation. Specifically, the measurement of PTM dynamics across the time course of infection can be leveraged to investigate immune evasion mechanisms and enhanced transmission. Furthermore, the findings from this study and other studies could serve as a resource for future investigations on newer SARS-COV-2 strains and a point of reference during the evolution of existing strains. Such an approach could aid in future pandemic preparedness in terms of finding novel drug targets.

**Limitations of the study**

We performed a temporal multi-OMICs study of host response to SARS-CoV-2 infection using a human lung epithelial cell line model. Though we have highlighted a number of interesting and potentially
valuable findings in terms host-directed therapeutic targets, one of the key limitations of this study is that the viral strain that we used is one of vast number of SARS-CoV-2 strains being studied, and is from the early days of the pandemic. The current SARS-CoV-2 strain in circulation could be very different from the strain that we studied and hence more multi-OMICS studies are required to find common targets for host-directed therapy.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **METHOD DETAILS**
  - Cell lines and reagents
  - Virus strains, stock preparation, plaque assay, and in vitro infection
  - SARS-CoV-2 infection and cell culture
  - NGS library preparation for RNA-Seq analysis
  - Next-Generation sequencing of transcriptome and raw data acquisition
  - Transcriptome analysis
  - Sample preparation for mass spectrometry analysis
  - Fe-NTA-based phosphopeptides enrichment
  - Liquid chromatography-tandem mass spectrometry analysis
  - Mass spectrometry data analysis
  - Metabolomics sample preparation and mass spectrometry analysis
  - Cytokine array analysis
  - Western blot analysis
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Kinase motif prediction
  - Structural analysis of phosphorylation sites

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.isci.2022.105895.

ACKNOWLEDGMENTS

We thank the Proteomics and Modomics Experimental Core Facility (PROMEC), Norwegian University of Science and Technology (NTNU), for support and expertise on LC-MS instrumentation. PROMEC is funded by the Faculty of Medicine and Health Sciences at NTNU and the Central Norway Regional Health Authority. Data storage and handling are supported under the NIRD/Notur project NN9036K. We thank Barbara Van Loon, IKOM, NTNU, for providing us with antibodies to assess cell cycle and DNA damage response. We thank Wenqi Wang, University of California, Irvine, USA for providing pYAP (S61) antibody. This research was funded by the Research Council of Norway (FRIMEDBIO “Young Research Talent” Grant 263168 to R.K.K.; Onsager fellowship from NTNU (to R.K.K.), the European Regional Development Fund for the Mobilitas Pluss Project MOBTT39 (to D.K.) and Centres of Excellence Funding Scheme Project 223255/F50 (to CEMIR). The FIMM Metabolomics Unit is supported by HiLIFE and Biocenter, Finland.

AUTHOR CONTRIBUTIONS

Conceptualization, S.M.P., D.K., and R.K.K.; Methodology, S.M.P., D.K., and R.K.K.; Formal Analysis, S.M.P., Y.S., M.W.G., and R.K.K.; Investigation, S.M.P., H.K., A.N., L.H., and D.K.; Data Curation, Y.S. and M.G.; Writing – Original Draft, S.M.P. and Y.S.; Writing – Review and Editing, S.M.P., Y.S., and R.K.K.; Supervision: R.K.K.; Project Administration: R.K.K.; Funding Acquisition, T.E., D.K., and R.K.K.

DECLARATION OF INTERESTS

The authors declare no competing interests.
REFERENCES

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544. https://doi.org/10.1038/s41564-020-0599-z.

2. Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9.

3. Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., Hohmann, E., Chu, H.Y., Luetkemeyer, A., Kline, S., et al. (2020). Remdesivir for the treatment of covid-19 - final report. N. Engl. J. Med. 383, 1813–1826. https://doi.org/10.1056/NEJMoa2007764.

4. Zhou, S., Hill, C.S., Sarkar, S., Tse, L.V., Woodburn, B.M.D., Schnaiz, R.F., Sheahan, T.P., Baric, R.S., Heise, M.T., and Swanstrom, R. (2021). beta-d-N4-hydroxyctydineinhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J. Infect. Dis. 224, 415–419. https://doi.org/10.1093/infdis/jiaa247.

5. Ledford, H. (2021). COVID antiviral pills: what scientists still want to know. Nature 599, 358–359. https://doi.org/10.1038/d41586-020-0695-z.

6. Wei, J., Alfajari, M.M., DeWeirtd, P.C., Hanna, R.E., Lu-Culligan, W.J., Cai, W.L., Strine, M.S., Zhang, S.M., Gaziano, V.R., Schmitz, C.O., et al. (2021). Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell 184, 78–91.e13. https://doi.org/10.1016/j.cell.2020.10.028.

7. Israeli, M., Finkel, Y., Yahalom-Ronen, Y., Paran, N., Chitaru, T., Israeli, O., Cohen-Gihon, I., Altalmon, M., Falach, R., Rotem, S., et al. (2022). Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2. Nat. Commun. 13, 2237. https://doi.org/10.1038/s41467-022-29896-z.

8. Kratzel, A., Kelly, J.N., V'Kovski, P., Portmann, J., Bruggemann, Y., Todt, D., Ebert, N., Shrestha, N., Plattet, P., Staab-Weimitz, C.A., et al. (2021). A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets. iScience 26, 105895, January 20, 2023.

9. Goujon, C., Rebendenne, A., Roy, P., Bonaventure, B., Valadão, A.C., Desmaret, L., Rouille, Y., Tauzi, M., Arnaud-Arnould, M., Giovannini, D., and et al. (2021). Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs. Res Sq https://doi.org/10.21203/rs.3.rs-555275/v1.

10. Baggen, J., Persoons, L., Vanstraelens, E., Jansen, S., van Looveren, D., Boecke, B., Geudens, V., De Man, J., Jochemans, D., Wauters, J., et al. (2021). Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nat. Genet. 53, 435–444. https://doi.org/10.1038/s41588-021-00805-2.

11. Zhu, Y., Feng, F., Hu, G., Wang, Y., Yu, Y., Zhu, Y., Xu, W., Cai, X., Sun, Z., Han, W., et al. (2021). A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. Nat. Commun. 12, 961. https://doi.org/10.1038/s41467-021-21213-4.

12. Schneider, W.M., Luna, J.M., Hoffmann, H.H., Sanchez-Rivera, F.J., Lee, A.A., Ashbrook, A.W., Le Pen, J., Ricardo-Lax, I., Michalidis, E., Peace, A., et al. (2021). Genome-Scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. Cell 184, 120–132.e14. https://doi.org/10.1016/j.cell.2020.12.006.

13. Wang, R., Simoneau, C.R., Kulsuptrakul, J., Schindlbeck, T.P., Baric, R.S., Heise, M.T., and Akusjarvi, S., Ambikan, A.T., Mikaeloff, F., Saconn, E., Vegvari, A., Benfetras, R., Sperk, M., Stahliberg, M., et al. (2020). CRISPR screens reveal host factors for SARS-CoV-2 infection. Cell 184, 106–119.e14. https://doi.org/10.1016/j.cell.2020.12.004.

14. Daniloski, Z., Jordan, T.X., Wessels, H.H., Hoagland, D.A., Kasela, S., Legut, M., Muller, A.C., Rebsamen, M., Cohen-Gihon, I., and Munch, C. (2020). Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2. Cell 184, 92–105.e16. https://doi.org/10.1016/j.cell.2020.10.030.

15. Zhao, Z., Zhao, Y., Zhou, Z., Wang, X., Zhang, T., and Zuo, W. (2020). Single-cell analysis identified lung progenitor cells in COVID-19 patients. Cell Prolif 53, e12931. https://doi.org/10.1111/cpr.12931.

16. Park, J.H., and Lee, H.K. (2020). Re-Analysis of single cell transcriptome reveals that the NRU3C1-CXCL8-neutrophil Axis determines the severity of COVID-19. Front. Immunol. 11, 2145. https://doi.org/10.3389/fimmu.2020.02145.

17. Singh, M., Bansal, V., and Fescolotte, C. (2020). A single-cell RNA expression map of human coronavirus entry factors. Cell Rep. 32, 108173. https://doi.org/10.1016/j.celrep.2020.108173.

18. Klann, K., Bojkova, D., Tascher, G., Ciesek, S., Munch, C., and Cinati, J. (2020). Growth factor receptor signaling identifies interacting proteins and targets SARS-CoV-2 replication. Mol. Cell. 80, 164–174.e4. https://doi.org/10.1016/j.molcel.2020.08.006.

19. Appelberg, S., Gupta, S., Svensson, Akusjarvi, S., Ambikan, A.T., Mikaeloff, F., Saconn, E., Vegvari, A., Benfetras, R., Sperk, M., Stahliberg, M., et al. (2020). The global phosphorylation landscape of SARS-CoV-2 infection. Cell 182, 685–712.e19. https://doi.org/10.1016/j.cell.2020.06.034.

20. Klann, K., Bojkova, D., Tascher, G., Ciesek, S., Munch, C., and Cinati, J. (2020). The global phosphorylation landscape of SARS-CoV-2 infection. Cell 182, 685–712.e19. https://doi.org/10.1016/j.cell.2020.06.034.

21. Grenga, L., Gallais, F., Pible, O., Gaillard, J.C., Gouveia, D., Batina, H., Bazaline, N., Ruat, S., Culotta, K., Minetti, G., et al. (2020). Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines. Emerg. Microbes Infect. 9, 1712–1721. https://doi.org/10.1080/22221751.2020.1791737.

22. Bojkova, D., Klann, K., Koch, B., Widera, M., Krause, D., Ciesek, S., Cinati, J., and Munch, C. (2020). Proteomics of SARS-CoV-2-infected cells reveals therapy targets. Nature 583, 469–472. https://doi.org/10.1038/s41586-020-2332-7.

23. Gordon, D.E., Jiang, G.M., Bouhadou, M., Xu, S., Griner, K., White, K.M., O'Shea, M.J., Rezul, V.V., Guo, J.Z., Swaney, D.L., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459–468. https://doi.org/10.1038/s41586-020-2286-9.

24. Kandasamy, R.K., Vladimir, G.I., Snijder, B., Muller, A.C., Rebsamen, M., Bigenzahn, J.W., Munch, C., and Cinati, J. (2020). A time-resolved molecular map of the macrophage response to VSV infection. NPJ...
coronavirus 2 nucleocapsid protein. Glycobiology 31, 1080–1092. https://doi.org/10.1093/glycob/cwab044.
35. Ramirez Hernandez, E., Hernandez-Zimbron, L.F., Martinez Zuniga, N., Leal-Garcia, J.J., Ignacio Hernandez, V., Ucharima-Corona, L.E., Perez Campos, E., and Zenteno, E. (2021). The role of the SARS-CoV-2 S-protein glycosylation in the interaction of SARS-CoV-2/ACE2 and immunological responses. Viral Immunol. 34, 165–173. https://doi.org/10.1089/vim.2020.0174.
36. Nehme, Z., Pasqueraye, S., and Herbein, G. (2019). Control of viral infections by measure differences in metabolite uptake and excretion by mammalian cell lines. Metabolomics 15, 165–173. https://doi.org/10.1007/s11306-018-0659-7.
37. Conrad, R.J., and Ott, M. (2016). Therapeutics targeting protein acetylation perturb latency of human viruses. ACS Chem. Biol. 11, 669–680. https://doi.org/10.1021/acschembio.6b00999.
38. Sanchez, R., Meslamani, J., and Zhou, M.M. (2014). The bromodomain: from epigenome reader to druggable target. Biochim.Biophys. Acta 1839, 676–685. https://doi.org/10.1016/j.bbagen.2014.03.011.
39. Thaker, S.K., Ch'ng, J., and Christofk, H.R. (2019). Viral hijacking of cellular metabolism. BMC Biol. 17, 59. https://doi.org/10.1186/s12915-019-0679-9.
40. Wright Muelas, M., Roberts, I., Mughal, F., Jarrett, R.M., and Thiele, I. (2015). Prediction of metabolism alterations in mammalian cell cultures. Int. J. Mol. Sci. 16, 20371–20390. https://doi.org/10.3390/ijms161120371.
41. Heiman, R.M., Hume, A.J., Goel, R.K., Abo, K.M., Huang, J., Blum, B.C., Werder, R.B., Suder, E.L., Paul, I., Phanse, S., et al. (2020). Actionable cytotoxic host responses of human alveolar type 2 cells to SARS-CoV-2. Mol Cell 80, 1104–1122.e9. https://doi.org/10.1016/j.molcel.2020.11.028.
42. Sheng, Y., Vinjamuri, A., Alvarez, M.R.S., Xie, Y., McGrath, M., Chen, S., Barboza, M., Frieman, M., and Lebrilla, C.B. (2022). Host cell glycoalkal symbol remodeling reveals SARS-CoV-2 spike protein glycomic binding sites. Front. Mol. Biosci. 9, 799703. https://doi.org/10.3389/fmolb.2022.799703.
43. Matsuoka, K., Imashiki, N., Ohno, M., Ode, H., Nakata, Y., Kubota, M., Sugimoto, A., Imashiki, M., Yokomaku, Y., and Iwatanii, Y. (2022). SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a glycoprotein homodimer. J. Biol. Chem. 298, 101724. https://doi.org/10.1074/jbc.T201107.120274.
44. Superek, N.T., Shahajan, A., Gleinich, A.S., Rouhani, D.S., Heiss, C., Chapla, D.G., Moremen, K.W., and Azadi, P. (2021). Variable postranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein. Glycobiology 31, 1080–1092. https://doi.org/10.1093/glycob/cwab044.
45. Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.C., Uhli, S., Hoagland, D., Molter, R., Jordan, T.X., Oishi, K., Panis, M., Sachs, D., et al. (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e9. https://doi.org/10.1016/j.cell.2020.04.026.
46. Finkel, Y., Gluck, A., Nachshon, A., Winkler, R., Fisher, T., Rozman, B., Mizrahi, O., Lubelsky, Y., Zuckerman, B., Slobodin, B., et al. (2021). SARS-CoV-2 uses a multisegmented strategy to impede host proteasome function. iScience 24, 102477. https://doi.org/10.1016/j.isci.2021.102477.
gene expression by SARS-CoV-2 in contrast to SARS-CoV. J. Proteome Res. 21, 459–469. https://doi.org/10.1021/acs.jproteome.1c00783.

54. Saccon, E., Chen, X., Mikaeloff, F., Rodriguez, J. E., Szekely, L., Vinhas, B. S., Krishnan, S., Byaradddy, S. N., Frisan, T., Veygari, A., et al. (2021). Cell-type-resolved quantitative proteomics map of interferon resistance against SARS-CoV-2. Science 24, 102420. https://doi.org/10.1126/sci.2021.102420.

55. Zechia, J., Lee, C.Y., Bayer, F. P., Meng, C., Grass, V., Zerweck, J., Schnatbaum, K., Michler, T., Pichlmair, A., Ludwig, C., and Kuster, B. (2020). Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing. Mol. Cell Proteomics 19, 1503–1522. https://doi.org/10.1074/mcp.RA120.021614.

56. El-Diwany, R., Soliman, M., Sugawara, S., Breitwieser, F., Ksait, A., Coggiana, C., Sangal, N., Chattergoon, M., Bailey, J. R., Siliciano, R. F., et al. (2018). CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. J. Biol. Chem. 293, 102498. https://doi.org/10.1074/jbc.M118.00937-x.

57. Kommadath, A., Bao, H., Choi, I., Reecy, J. M., Koltes, J. E., Fritz-Waters, E., Esley, C. J., Grant, J. R., Rowland, R. R., Tuggle, C. K., et al. (2017). Genetic architecture of gene expression underlying variation in host response to porcine reproductive and respiratory syndrome virus infection. Nat. Rev. 7, 46203. https://doi.org/10.1038/srep46203.

58. Kim, H., Subbannayya, Y., Humphries, F., Skegson, A., Pinto, S. M., Giambelluca, M., Espevik, T., Fitzgerald, K. A., and Kandasamy, R. K. (2021). UMP-CMP kinase 2 gene expression in macrophages is dependent on the IRF3-IFNAR signaling axis. PLoS One 16, e0258989. https://doi.org/10.1371/journal.pone.0258989.

59. Lai, J. H., Wu, D. W., Wu, C. H., Hung, L. F., Huang, K. Y., Ca, S. M., Chen, A., Chang, Z. F., and Ho, L. J. (2021). Mitochondrial CMPK2 mediates immunomodulatory and antiviral functions through IFN-dependent and IFN-independent pathways. iScience 24, 102498. https://doi.org/10.1016/j.isci.2021.102498.

60. Xu, Y., Johansson, M., and Karlsson, A. (2008). Human UMP-CMP kinase 2, a novel nucleoside monophosphate kinase localized in mitochondria. J. Biol. Chem. 283, 1563–1571. https://doi.org/10.1074/jbc.M707979200.

61. Tsao, N., Lee, M. H., Zhang, W., Cheng, Y. C., and Chang, Z. F. (2015). The contribution of CMP kinase to the efficiency of DNA repair. Cell Cycle 14, 354–363. https://doi.org/10.4161/cc.15384104.2014.967816.

62. Miettinen, M., Sarenev, T., Julkunen, I., and Matikainen, S. (2001). IFN activates toll-like receptor gene expression in viral infections. Genes Imm. 2, 349–355. https://doi.org/10.1038/sj.gene.6365371.
degradation of pattern recognition receptor DDX58/RIG-I. Autophagy 16, 408–418. https://doi.org/10.2174/156989261666619060821016.

165103.

19. Tatematsu, M., Funami, K., Ishii, N., Seya, T., Obuse, C., and Matsumoto, M. (2015). LRRCS9 regulates trafficking of nucleic acid-sensing TLRs from the endoplasmic reticulum via association withUNC93B1. J. Immunol. 195, 4933–4942. https://doi.org/10.4049/jimmunol.1501305.

20. Wei, X., Liu, Z., Yang, R., Yang, J., Zhang, S., Liang, J. H., Fang, Y., Gentili, M., Leary, C. N. O., Elledge, S. J., et al. (2021). SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antagonists. Nat. Commun. 12, 3818. https://doi.org/10.1038/s41467-021-24007-w.

21. Zhang, Y., Guo, R., Kim, S. H., Shah, H., Zhang, S., Liang, J. H., Yang, J., Gentili, M., Leary, C. N. O., Elledge, S. J., et al. (2021). SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication. Nat. Commun. 12, 1676. https://doi.org/10.1038/s41467-021-21993-z.

22. Sanchez, E. L., and Laguonoff, M. (2015). Viral activation of cellular metabolism. Virology 479–480, 609–618. https://doi.org/10.1016/j.virol.2015.02.038.

23. Mayer, K. A., Stockl, J., Ziltinger, G. J., and Gualdoni, G. A. (2019). Hijacking the supplies: metabolism as anovel facet of virus-host interaction. Front. Immunol. 10, 1533. https://doi.org/10.3389/fimmu.2019.01533.

24. Icard, P., Lincet, H., Wu, Z., Coquerel, A., Forgez, P., Alifano, M., and Fournell, L. (2021). The key role of Warburg effect in SARS-CoV-2 replication and associated inflammation response. Biochimie 180, 169–177. https://doi.org/10.1016/j.biochi.2020.11.010.

25. Caslin, H. L., Abebayehu, D., Pinette, J. A., and Ryan, J. J. (2021). Lactate is ametabolic mediator that shapes immune cell fate and function. Front. Physiol. 12, 686845. https://doi.org/10.3389/fphys.2021.686845.

26. Codo, A. C., Davanzo, G. G., Monteiro, L. B., de Souza, G. F., Muraro, S. P., Virgilio-da-Silva, J. V., Prodonoff, J. S., Carregari, V. C., de Biagi Junior, C. A. O., Crunfi, F., et al. (2020). Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/Glycolysis-Dependent Axis. Cell Metab 32, 498–499. https://doi.org/10.1016/j.cmet.2020.07.015.

27. Moolamalla, S. T. R., Balasubramanian, R., Chauhan, R., Priyakumar, U. D., and Vinod, P. K. (2021). Host metabolic reprogramming in response to SARS-CoV-2 infection: a systems biology approach. Mol. Obes Path. 158, 105114. https://doi.org/10.1016/j.micopath.2021.105114.

28. Stubbs, B. J., Koutnik, A. P., Goldberg, E. L., Upadhyay, V., Tumbaugh, P. J., Verdin, E., and Newman, J. C. (2020). Investigating ketone bodies as immunometabolic countermeasures against respiratory viral infections. Med. (N.Y.) 1, 43–65. https://doi.org/10.1016/j.med.2020.06.008.

29. Caniglia, J. L., Asuthkar, S., Tsung, A. J., Guda, M. R., and Velpula, K. K. (2020). Immunopathology of gelatin-3: an increasingly promising target in COVID-19. F1000Res 9, 1078. https://doi.org/10.12688/f1000research.25979.2.

30. Puimboom, L. (2021). SARS-CoV-2, possible alternative virus receptors and pathophysiological determinants. Med. Hypotheses 146, 110368. https://doi.org/10.1016/j.mehy.2020.110368.

31. Malone, B., Uraková, N., Snijder, E. J., and Campbell, E. A. (2022). Structures and functions of coronavirus replication-transcriptioncomplexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 23, 21–39. https://doi.org/10.1038/s41592-021-00452-z.

32. Nabeel-Shah, S., Lee, H., Ahmed, N., Burke, G. L., Farhangoosmer, S., Ashraf, K., Pu, S., Graubart, U., Zhang, Y., Wei, H., et al. (2022). SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress granules to impair host stress response. Science 25, 103562. https://doi.org/10.1126/science.aas1640.

33. Ferguson, B. J., Mansur, D. S., Peters, N. E., Ren, H., and Smith, G. L. (2012). DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. Elife 1, e00047. https://doi.org/10.7554/eLife.00047.

34. Hatakeyama, D., Masuda, T., Miki, R., Ohtsuki, S., and Kuzuhara, T. (2021). In-vitro acetylation of SARS-CoV and SARS-CoV-2 nucleocapsid proteins by human PCAF and GCNS Biochem. Biophys. Res. Commun. 557, 273–279. https://doi.org/10.1016/j.bbrc.2021.03.173.

35. Dinesh, D. C., Chalupská, D., Silhan, J., Koutna, E., Novotná, R., Veverka, V., and Boura, E. (2020). Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein. PLoS Pathog. 16, e1009100. https://doi.org/10.1371/journal.ppat.1009100.

36. Ye, Q., West, A. M. V., Silletti, S., and Corbett, K. D. (2020). Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein. Protein Sci. 29, 1890–1901. https://doi.org/10.1002/pro.3907.

37. Yang, J., Anishchenko, I., Park, H., Peng, Z., Ovchinnikov, S., and Baker, D. (2020). Improved protein structure prediction using predicted interresidue orientations. Proc. Natl. Acad. Sci. USA 117, 1496–1503. https://doi.org/10.1073/pnas.1914677117.

38. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550. https://doi.org/10.1073/pnas.0506580102.

39. Harvey, K. F., Zhang, X., and Thomas, D. M. (2013). The Hippo pathway and human
cancer. Nat. Rev. Cancer 13, 246–257. https://doi.org/10.1038/ncr3458.

114. Wang, Z., Lu, W., Zhang, Y., Zou, F., Jin, Z., and Zhao, T. (2019). The hippo pathway and viral infections. Front. Microbiol. 10, 3033. https://doi.org/10.3389/fmicb.2019.03033.

115. Hansen, C.G., Moroishi, T., and Guan, K.L. (2015). YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol. 25, 499–513. https://doi.org/10.1016/j.tcb.2015.05.002.

116. Kim, M.K., Jing, J.W., and Bae, S.C. (2018). DNA binding partners of YAP/TAZ. BMB Rep. 51, 126–133. https://doi.org/10.5483/bmbrep.2018.51.3.015.

117. Wang, S., Xie, F., Chu, F., Zhang, Z., Yang, B., Dai, T., Gao, L., Wang, L., Ling, L., Jia, J., et al. (2017). YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKεarepsilin-mediated phosphorylation. Nat. Immunol. 18, 733–743. https://doi.org/10.1038/nii.2017.103.

118. Garcia, G., Wang, Y., Iрудayam, J.I., Gaczynski, A.V., Cario, S.C., Sen, C., Li, S., Li, Y., Kumar, A., Nielsen-Saines, K., et al. (2022). Hippo signaling pathway activation during SARS-CoV-2 infection contributes to host antiviral response. Preprint at bioRxiv https://doi.org/10.1101/2022.04.07.487520.

119. Zhang, Q., Meng, F., Chen, S., Plouffe, S.W., Wu, S., Liu, S., Li, X., Zhou, R., Wang, J., Zhao, B., et al. (2017). Hippo signaling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade. Nat. Cell Biol. 19, 362–374. https://doi.org/10.1038/ncc.3496.

120. Wang, W., Xiao, Z.D., Li, X., Aziz, K.E., Gan, B., Johnson, R.L., and Chen, J. (2015). AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat. Cell Biol. 17, 490–499. https://doi.org/10.1038/ncc.3113.

121. Granas, K., Armgarden, L., Lonn, P., Mazurkiewicz, M., Blokzijl, A., Zieba, A., and Soderberg, O. (2015). Crosstalk between hippo and TGF-beta: subcellular localization of YAP/TAZ/smad complexes. J. Mol. Biol. 427, 3407–3415. https://doi.org/10.1016/j.jmb.2015.04.015.

122. Zhao, B., Wei, X., Li, W., Udan, R.S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007). Inactivation of YAP oncoprotein by emerging pathisms of regulation cell contact inhibition and tissue growth control. Genes Dev. 21, 2747–2761. https://doi.org/10.1101/gad.160297.108.

123. Pennington, K.L., Chan, T.Y., Torres, M.P., and Andersen, J.L. (2018). The dynamic and stress-adaptive signaling hub of 14-3-3 emerging pathisms of regulation cell contact-dependent protein-protein interactions. Oncogene 37, 5587–5604. https://doi.org/10.1038/s41388-018-0348-3.

124. Enzo, E., Santinon, G., Pocaterra, A., Aragona, M., Bresolin, S., Forcato, M., Grifoni, D., Pession, A., Zanconato, F., Guzzo, G., et al. (2013). Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 34, 1349–1370. https://doi.org/10.15252/embj.201490379.

125. Koo, J.H., and Guan, K.L. (2018). Interplay between YAP/TAZ and metabolism. J. Cell Metab. 28, 196–206. https://doi.org/10.1016/j.jcmet.2018.07.010.

126. Sanjaya, A., Gosaen, H., Setiawan, I., Gunadi, J.W., Limyati, Y., and Lesmana, R. (2021). Elaborating the Physiological role of YAP as a glucose metabolism regulator: A systematic Review. Cell. Physiol. Biochem. 55, 193–205. https://doi.org/10.3254/000000359.

127. Cottini, F., Hideshima, T., Xu, C., Sattler, M., Dorri, M., Agnelli, L., ten Hacken, E., Bertlaccio, M.T., Antonini, E., et al. (2014). Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat. Med. 20, 599–606. https://doi.org/10.1038/nm.3562.

128. Raj, N., and Barn, S. (2019). Reciprocal crosstalk between YAP1/hippo pathway and the p53 family proteins: mechanisms and outcomes in cancer. Front. Cell Dev. Biol. 7, 159. https://doi.org/10.3389/fcell.2019.00159.

129. Yuan, F., Wang, J., Li, R., Zhao, X., Zhang, Y., Liu, B., Lei, Y., and Hu, Y. (2019). A new regulatory mechanism between PS3 and YAP crosstalk by SIRT1 mediated deacetylation to regulate cell cycle and apoptosis in AS547 cell lines. Cancer Manag Res. 11, 8619–8633. https://doi.org/10.2174/CMAR.5214626.

130. Lei, J., and Hilgenfeld, R. (2017). RNA-virus sensing proteases counteracting host innate immunity. FEBS Lett. 591, 3190–3210. https://doi.org/10.1002/1873-3468.12827.

131. Rubin, E., Mittnacht, S., Villa-Moruzzi, E., and Rudloff, J.W. (2001). Site-specific and temporally-regulated retinoblastoma protein phosphorylation by p53: identification of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) phosphorylation in mitosis. Biocells Rep. 34. https://doi.org/10.4247/biocs.20140051.

132. Rogakou, E.P., Pilk, D.R., Orr, A.H., Ivanova, V.S., and Bonner, W.M. (1998). DNA double-stranded breaks induce histone H2AX phosphorylation on serine 136. J. Biol. Chem. 273, 5858–5868. https://doi.org/10.1015/jbc.1998.05154.13.

133. Zhou, Y., Lee, J.H., Jiang, W., Crowe, J.L., Zha, S., and Paull, T.T. (2017). Regulation of the DNA damage response by DNA-PKcs inhibitory phosphorylation of ATM. Mol. Cell 65, 91–104. https://doi.org/10.1016/j.molcel.2016.11.004.

134. Lentine, B., Antonucci, L., Hunc, R., Edwards, J., Marallano, V., and Krucher, N.A. (2012). Diphosphorylation of threonine-821 of the retinoblastoma tumor suppressor protein (Rb) is required for apoptosis induced by UV and Cdk inhibition. Cell Cycle 11, 3234–3230. https://doi.org/10.4161/cc.21693.

135. Malik, A., Rustagi, A., Zhao, N.Q., Rocque, J., Martinez-Colon, G.J., McKechnie, J.L., Ivens, G.T., Ranganath, T., Yang, R., Hollis, T., et al. (2020). A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 26, 1070–1076. https://doi.org/10.1038/s41591-020-0944-y.

136. Martin-Sanchez, L., Lewinski, M.K., Pache, L., Stoneham, C.A., Yin, X., Becker, M.E., Pratt, O., and Andersen, J.L. (2018). The dynamic and stress-adaptive signaling hub of 14-3-3 emerging pathisms of regulation cell contact-dependent protein-protein interactions. Oncogene 37, 5587–5604. https://doi.org/10.1038/s41388-018-0348-3.
153. Perez-Riverol, Y., Bai, J., Bandila, C., Garcia-Sesidodos, D., Hiewapathirana, S., Kamatchinathan, S., Kundi, D.J., Prakash, A., Frels-Arqui, P., Eisenacher, M., et al. (2022). The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543–D552. https://doi.org/10.1093/nar/gkbai038.

154. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 57–63. https://doi.org/10.1093/bioinformatics/bts535.

155. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Bioinformatics 30, 455–462. https://doi.org/10.1093/bioinformatics/btu861.

156. Gu, Z., Eils, R., and Schlesner, M. (2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849. https://doi.org/10.1093/bioinformatics/btw313.

157. Stephens, M. (2017). False discovery rates: a new deal. Biostatistics 18, 757–793. https://doi.org/10.1093/biostatistics/khx041.

158. Ignatiadis, N., Klaus, B., Zaugg, J.B., and Wisniewski, J.R., Zougman, A., Nagaraj, N., and Mann, M. (2014). Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370. https://doi.org/10.1126/science.abe9403.

159. Kern, D.M., Sorum, B., Mali, S.S., Hoel, C.M., Rezelj, V.V., Ulferts, S., Braberg, H., Jureka, A.S., Obernier, K., Guo, J.Z., Batra, J., et al. (2020). Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370. https://doi.org/10.1126/science.abe9403.

160. Gordon, D.E., Hiatt, J., Bouhaddou, M., Rezelj, V.V., Ulferts, S., Braberg, H., Jureka, A.S., Obernier, K., Guo, J.Z., Batra, J., et al. (2020). Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370. https://doi.org/10.1126/science.abe9403.

161. Kotecha, A., Bautista, D.M., and Brohawn, S.G. (2021). Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs. Nat. Struct. Mol. Biol. 28, 573–582. https://doi.org/10.1038/s41594-021-00619-0.

162. Clark, L.K., Green, T.J., and Petit, C.M. (2021). Structure of nonstructural protein 1 from SARS-CoV-2. J. Virol. 95. https://doi.org/10.1128/JVI.02019-20.

163. Yuan, S., Peng, L., Park, J., Hu, Y., Devarker, S.C., Dong, M.B., Shen, Q., Wu, S., Chen, S., Lomakin, I.B., and Xiong, Y. (2020). Nonstructural protein 1 of SARS-CoV-2 is a potent Pathogenicity factor redirecting host protein synthesis machinery toward viral RNA. Mol. Cell 80, 1055–1066.e6. https://doi.org/10.1016/j.molcel.2020.10.034.
### STAR★METHODS

#### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| anti-β-Actin        | Abcam  | Cat#6276   |
| anti-OAS1           | Cell Signaling Technology | Cat#14498 |
| anti-ISG15          | Cell Signaling Technology | Cat#2734S |
| anti-TRIM5          | Cell Signaling Technology | Cat#14326 |
| anti-RNase-L        | Cell Signaling Technology | Cat#27281 |
| anti-MX1            | Cell Signaling Technology | Cat#37849 |
| anti-p53            | Cell Signaling Technology | Cat#9282 |
| anti-phospho p53 (Ser15) | Cell Signaling Technology | Cat#82530 |
| anti-TYKi           | Novus Biologicals | Cat#NBP1-80653 |
| anti-phospho γH2AX (Ser139) | Cell Signaling Technology | Cat#2577 |
| anti-phospho TBK1 (Ser172) | Cell Signaling Technology | Cat#5483 |
| anti-phospho IRF3 (Ser396) | Cell Signaling Technology | Cat#29047 |
| anti-phospho JNK (Thr183/Tyr185) | Cell Signaling Technology | Cat#4668 |
| anti-phospho ERK1/2 (Thr202/Tyr204) | Cell Signaling Technology | Cat#4370 |
| anti-phospho p38 (Thr180/Tyr182) | Cell Signaling Technology | Cat#4511 |
| anti-phospho STAT1 (Ser727) | Cell Signaling Technology | Cat#8826 |
| anti-phospho STAT3 (Tyr705) | Cell Signaling Technology | Cat#9145 |
| anti-phospho EIF2α (Ser51) | Cell Signaling Technology | Cat#3398 |
| anti-phospho YAP1 (Ser61) | kind gift from Dr. Wenqi Wang, University of California, Irvine | N/A |
| **Bacterial and virus strains** | | |
| hCoV-19/Norway/Trondheim-S15/2020 strain | Ianevski et al. | N/A |
| **Chemicals, peptides, and recombinant proteins** | | |
| PhosStop phosphatase inhibitor cocktail tablets | Roche | Cat#4906837001 |
| Fetal bovine serum (FBS) | Thermo Fisher Scientific | Cat#10082 |
| DMEM-F12 medium | Thermo Fisher Scientific | Cat#11320033 |
| QIAzol lysis reagent | Qiagen | Cat#79306 |
| VIVACON 500 filter units | Sartorius Stedim Biotech | Cat#NV01H21 |
| Sequencing-grade trypsin | Pierce, Thermo Fisher Scientific | Cat#90058 |
| Macro Spin columns (Vydac C18, SS18V 30-300 μg) | The NEST Group | |
| 3M Empore Discs, Cation Extraction | 3M | Cat#3M~2251 |
| Ni-NTA Superflow resin | Qiagen | Cat#30410 |
| Fe(III)chloride, anhydrous | Sigma Aldrich | Cat#451649 |
| Acclaim PepMap 100 2 cm trap column | Thermo Fisher Scientific | N/A |
| Acclaim PepMap 100C18 HPLC Column, 50 cm | Thermo Fisher Scientific | N/A |
| SeQuant ZIC-phILIC (2.1 x 100 mm, 5-μm particles) | Merck | Cat#150462 |
| Super-Signal West Femto Substrate | Thermo Fisher Scientific | Cat#34094 |

(Continued on next page)
| REAGENT or RESOURCE                                                      | SOURCE                        | IDENTIFIER       |
|----------------------------------------------------------------------|-------------------------------|------------------|
| Critical commercial assays                                           |                               |                  |
| BCA Protein Assay Kit                                                | Thermo Fisher Scientific       | Cat#23225        |
| TruSeq Stranded mRNA LT sample preparation kit                       | Illumina                      | Cat#20020594     |
| TMTtaxplex Isobaric Label Reagent Set                                 | Thermo Fisher Scientific       | Cat#90066        |
| Mass spectrometry metabolite library kit                             | Sigma Aldrich                 | Cat#MSMLS-1EA     |
| Proteome Profiler Human Cytokine Array Kit                           | R&D Systems                   | Cat#ARY022B      |
| PTMScan® Acetyl-Lysine Motif (Ac-K) Kit                              | Cell Signaling Technology     | Cat#13416        |
| Deposited data                                                        |                               |                  |
| RNA-Seq of SARS-CoV2 infected Calu-3 cells                           | This paper                    | E-MTAB-12134     |
| Proteomics, phosphoproteomics and acetylamics of SARS-CoV2 infected  | This paper                    | PRIDE Project ID: PXD032677 |
| Molecular Signatures Database for gene set enrichment analysis MSigDB| Subramanian et al.112          |                  |
| Post-Translational Modification Signatures (PTMsigDB)                 | Krug et al.162                |                  |
| Experimental models: Cell lines                                      |                               |                  |
| Calu-3                                                                | ATCC                          | Cat#HTB-55       |
| Vero-E6                                                               | ATCC                          | Cat#CRL-1586     |
| Software and algorithms                                               |                               |                  |
| HiSeq Control Software                                                | Illumina                      | HCS, HD 3.4.0.38 |
| Real-Time Analysis Software                                          | Illumina                      | RTA, 2.7.7       |
| Picard tools (2.19.2)                                                | Broad Institute               |                  |
| “Spliced Transcripts Alignment to a Reference” (STAR)                | Dobin et al.154               |                  |
| GenomicAlignments (1.24.0) package                                   | Bioconductor                  |                  |
| Bioconductor DESeq2 (1.28.1) package                                 | Love et al.155                |                  |
| Proteome Discoverer platform (v2.4)                                   | Thermo Fischer Scientific     | N/A              |
| TraceFinder 4.1                                                       | Thermo Fischer Scientific     | N/A              |
| ImageJ                                                                | NIH                           |                  |
| limma (v3.44.3)                                                      | Bioconductor                  |                  |
| proDA (v1.2.0) package                                               | Bioconductor                  |                  |
| enrichR (v3.0) R package                                             | r-project                     |                  |
| Metaboanalyst 5.0                                                    | Metaboanalyst                 |                  |
| heatmap package (v1.0.12)                                             | r-project                     |                  |
| ChemSpider                                                            |                                |                  |
| NetPhos 3.1                                                           | Blom et al.154                |                  |
| UCSF ChimeraX                                                        | Goddard et al.165             |                  |
| TrRosetta                                                             | Yang et al.111                |                  |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Richard K. Kandasamy (richard.k.kandasamy@ntnu.no).

Materials availability
This study did not generate unique new reagents.

Data and code availability
- The RNA-Seq data from the current study are available from the ArrayExpress database under the accession number E-MTAB-12134.
- The mass spectrometry proteomics raw data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repositories with the dataset identifier PXD032677.
- The processed data is also available for querying at www.sarscov2map.org.

METHOD DETAILS

Cell lines and reagents
Non-small-cell human lung cancer Calu-3 obtained from ATCC (HTB-55) were grown in DMEM-F12 medium supplemented with 100 μg/mL streptomycin and 100 U/mL penicillin (Pen/Strep), 2 mM L-glutamine, 10% FBS, and 0.25% sodium bicarbonate (Sigma-Aldrich, St. Louis, USA) (complete media). Kidney epithelial cells extracted from an African green monkey (Vero-E6) were grown in DMEM medium supplemented with 10% FBS and Pen-Strep. The cell lines were maintained at 37°C with 5% CO2.

Virus strains, stock preparation, plaque assay, and in vitro infection
All experiments involving live SARS-CoV-2 were performed in compliance with NTNU’s guidelines for Biosafety Level 3 (BSL-3) containment procedures in approved laboratories. All experiments were performed in at least three biologically independent samples. hCoV-19/Norway/Trondheim-S15/2020 strain from our previous study1 were amplified in a monolayer of Vero-E6 cells in DMEM media containing Pen/Strep and 0.2% BSA. The media from the viral culture were serially diluted from 10^-2 to 10^-7 in serum-free media containing 0.2% BSA. The dilutions were applied to a monolayer of Vero-E6 cells in 24-well plates. After 1 h, cells were overlaid with the virus growth medium containing 1% carboxymethyl cellulose and incubated for 72 h. The cells were fixed and stained with crystal violet dye, and the plaques were calculated in each well and expressed as plaque-forming units per mL (pfu/mL).

SARS-CoV-2 infection and cell culture
Calu-3 cells were grown in complete DMEM-F12 media in a humidified incubator at 37°C in the presence of 5% CO2. The medium was replaced with DMEM-F12 containing 0.2% BSA and Pen-Strep prior to infection experiments. The cells were mock- or virus-infected at an MOI of 0.1 for 0, 3, 6, 12, 24, and 48 h. At each time point, the samples were washed twice with 1x TBS buffer and harvested in QIAzol lysis reagent (Qiagen, Germany) (for RNASeq) followed by DNAse digestion (Qiagen, Germany) treatment on the RNeasy Mini.
columns, according to the manufacturer’s protocol. SDS lysis buffer 4% SDS, 50 mM TEABC (Sigma Aldrich), and PhosStop inhibitors (Roche) was used to extract the proteins. The lysates for proteomic and PTMomic analysis were heat-inactivated at 90°C for 10 min and stored at −80°C until further processing.

**NGS library preparation for RNA-Seq analysis**

The total RNA amount was quantified using the Qubit 2.0 Fluorometric Quantitation system (Thermo Fisher Scientific, Waltham, MA, USA), and the RNA integrity number (RIN) was determined using the Experion Automated Electrophoresis System (Bio-Rad, Hercules, CA, USA). RNA-seq libraries were prepared with the TruSeq Stranded mRNA LT sample preparation kit (Illumina, San Diego, CA, USA) using Sciclone and Zephyr liquid handling workstations (PerkinElmer, Waltham, MA, USA) for pre- and post-PCR steps, respectively. Library concentrations were quantified with the Qubit 2.0 Fluorometric Quantitation system (Life Technologies, Carlsbad, CA, USA). The size distribution was assessed using the Experion Automated Electrophoresis System (Bio-Rad, Hercules, CA, USA). For sequencing, samples were diluted and pooled into NGS libraries in equimolar amounts.

**Next-Generation sequencing of transcriptome and raw data acquisition**

Expression profiling libraries were sequenced on a HiSeq 4000 instrument (Illumina, San Diego, CA, USA) following a 50-base-pair, single-end recipe. Raw data acquisition (HiSeq Control Software, HCS, HD 3.4.0.38) and base calling (Real-Time Analysis Software, RTA, 2.7.7) were performed on the instrument, while the subsequent raw data processing off the instruments involved two custom programs based on Picard tools (2.19.2) ([https://github.com/epigen/picard/](https://github.com/epigen/picard/), [https://broadinstitute.github.io/picard/](https://broadinstitute.github.io/picard/)). In the first step, base calls were converted into lane-specific, multiplexed, unaligned BAM files suitable for long-term archival (IlluminaBasecallsToMultiplexSam, 2.19.2-CeMM). In the second step, archive BAM files were demultiplexed into sample-specific, unaligned BAM files (IlluminaSamDemux, 2.19.2-CeMM).

**Transcriptome analysis**

NGS reads were mapped to the Genome Reference Consortium GRCh38 assembly via “Spliced Transcripts Alignment to a Reference” (STAR) utilizing the “basic” Ensembl transcript annotation from version e100 (April 2020) as reference transcriptome. Since the hg38 assembly flavor of the UCSC Genome Browser was preferred for downstream data processing with Bioconductor packages for entirely technical reasons, Ensembl transcript annotation had to be adjusted to UCSC Genome Browser sequence region names. STAR was run with options recommended by the ENCODE project. Aligned NGS reads overlapping Ensembl transcript features were counted with the Bioconductor (3.11), GenomicAlignments (1.24.0) package via the summarizeOverlaps function in Union mode, taking into account that the Illumina TruSeq stranded mRNA protocol leads to the sequencing of the first strand so that all reads needed inverting before counting. Transcript-level counts were aggregated to gene-level counts, and the Bioconductor DESeq2 (1.28.1) package was used to test for differential expression based on a model using the negative binomial distribution.

The initial exploratory analysis included principal component analysis (PCA), multi-dimensional scaling (MDS), sample distance, and expression heatmap plots, all annotated with variables used in the expression modeling (ggplot2, 3.3.2, and Bioconductor ComplexHeatmap, 2.4.3), as well as volcano plots (Bioconductor EnhancedVolcano, 1.6.0). Biologically meaningful results were extracted from the model, log2-fold values were shrunk with the CRAN ashr (2.2-47) package, while two-tailed pvalues obtained from Wald testing were adjusted with the Bioconductor Independent Hypothesis Weighting (IHW, 1.16.0) package. The resulting gene lists were annotated and filtered for significantly differentially up- and down-regulated genes.

**Sample preparation for mass spectrometry analysis**

The cell lysates were sonicated using a probe sonicator (Branson Digital Sonifier, Branson Ultrasonics Corporation, USA) on ice for 5-10 min (20% amplitude, 10 cycles). The lysates were then heated at 95°C and centrifuged at 12,000 rpm each for 10 min, respectively. The concentration of proteins was determined by the Bicinchoninic acid (BCA) assay (Pierce, Thermo Fisher Scientific, Waltham, MA). A total of 300 µg proteins per sample were used for downstream processing using the filter-aided sample preparation (FASP) method. Before FASP, the samples were reduced using Dithiothreitol (DTT) (Sigma Aldrich) at a final concentration of 100 mM at 99°C for 5 min, cooled to room temperature, and loaded onto pre-equilibrated
VIVACON 500 filter units (Sartorius Stedim Biotech, Germany). Briefly, the lysates were washed with 8 M urea in 100 mM Tris/HCl pH 8.5, alkylation with 50 mM iodoacetamide in 8 M Urea, 100 mM Tris/HCl solution, followed by washes with 8 M Urea and 50 mM TEAB. The protein samples were finally resuspended in 50 mM TEAB, pH 8.5, and digested with sequencing-grade trypsin (Pierce, Thermo Fisher Scientific) (enzyme to protein ratio 1:50) overnight at 37°C on a thermomixer. Post digestion, the filter units were centrifuged at 14,000 g for 20 min, followed by 50 mM TEAB and 0.5 M NaCl, respectively, and the process was repeated. Before TMT labeling, the pooled filtrates were acidified with 30% TFA and subjected to solid-phase extraction of peptide digests using Macro Spin columns (Vydac C18, SS18V 30-300 µg, The NEST Group, USA).

250 µg SPE purified peptides per sample were labeled with TMT6plex reagent (Thermo Fisher Scientific, USA) following the manufacturer’s instructions. The labeling efficiency and normalization of the mixing ratio were determined following a single injection measurement by LC-MS/MS. The TMT-labeled samples from each channel were pooled to equimolar ratios accordingly. For total proteome analysis, 60 µg of pooled peptides were evaporated to dryness using speedvac and fractionated using SCX StageTip-based fractionation as described earlier with minor modifications, including 8 punches of SCX material (3M – 2251) obtained using 14-Gauge needle tip. The remaining pooled TMT labeled peptide digest was subjected to phosphopeptide enrichment.

Fe-NTA-based phosphopeptides enrichment
Phosphopeptides from each biological replicate were enriched using in-house prepared Fe-NTA microtip columns. Briefly, Ni-NTA Superflow resin (Qiagen, Germany) was activated and coupled with 10 mM Fe(III) chloride solution (Sigma Aldrich, Germany). The activated slurry was resuspended in acetonitrile:methanol: 0.01% acetic acid (1:1:1) solution. Prior to enrichment, the peptides were acidified using 30% TFA and subjected to solid-phase extraction of peptide digests using Macro Spin columns (Vydac C18, SS18V 30-300 µg, The NEST Group, USA). The peptides were eluted in SPE-Phospho elution buffer (80% acetonitrile, 0.1% TFA) to achieve a peptide concentration of ~1 µg/µL. The eluate was incubated with an aliquot of activated Fe-NTA slurry on a rotary shaker at room temperature for 60 min. This was followed by centrifugation at 6,500 r.p.m. for 1 min at room temperature and transferring the flow-through to separate tubes for sequential acetyl enrichment. The bound peptides were washed with SPE-Phospho elution buffer thrice. The bound phosphopeptides were released using 50 µL freshly-prepared ammonia solution (~1.4%) and 1.5 µL 100 mM EDTA solution, pH 8, after incubation at room temperature for 10 min. After enrichment, the enriched phosphopeptides were loaded onto C8 StageTips to remove contaminating Fe-NTA particles, eluted, and evaporated to dryness using speedvac (Eppendorf, Germany). The enriched phosphopeptides were subjected to offline fractionation using SCX StageTips, as described earlier.

The flow-through from the phosphopeptide enrichment was pooled to 3 fractions, desalted using Waters C18 cartridge, and the eluate was lyophilized. The lyophilized peptide mixtures were dissolved in IAP buffer containing 50 mM MOPS pH 7.2, 10 mM sodium phosphate, and 50 mM NaCl. The Acetyl-lysine motif immunoaffinity beads (Cell Signaling Technology, USA) were washed twice with IAP buffer at 4 °C and then incubated with the peptide mixture for 4 h with gentle rotation. The unbound peptides were removed by washing the beads with ice-cold IAP buffer (3x) followed by ice-cold water (2x). The enriched peptides were eluted from the beads at room temperature twice using 0.15% TFA, followed by C18 StageTip-based cleanup before mass spectrometry analysis.

Liquid chromatography-tandem mass spectrometry analysis
All mass spectrometry data were acquired in centroid mode on a Q Exactive HF Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) coupled to Easy-nLC1200 nano-flow UHPLC (Thermo Scientific, Odense, Denmark). Spray voltage of 1.9 kV was applied with the transfer tube heated to 250°C and S-lens RF of 55%. Internal mass calibration was enabled (lock mass 445.12003 m/z). Tryptic peptides obtained from StageTip-based SCX fractionation from global proteome, phosphoproteome and acetylome fractions were reconstituted in 0.1% formic acid and loaded on an Acclaim PepMap 100 2 cm (3 µm C18 Aq) trap column (Thermo Fisher Scientific). Peptide separation was carried out using Acclaim PepMap 100C18 HPLC Column, 50 cm heated to 50°C using an integrated column oven. HPLC solvents consisted of 0.1% Formic acid in water (Buffer A) and 0.1% Formic acid, 80% acetonitrile in water (Buffer B). Peptide fractions were eluted at a flow rate of 250 nL/min by a non-linear gradient from 6 to 30% B over 110 min, followed by a stepwise increase to 60% B in 6 min and 95% B in...
Metabolomics sample preparation and mass spectrometry analysis

Metabolites were extracted from 100 μL of cell culture medium with 400 μL of cold extraction solvent (Acetonitrile: Methanol: Water, 40:40:20). Subsequently, samples were sonicated for 3 cycles with sweep mode (60s, power 60, and frequency 37), vortexed for 2 min, and centrifuged at 4°C, 14,000 rpm for 10 min. The supernatant was transferred to autosampler vials for LC-MS analysis. The extracts were analyzed with a Thermo Vanquish UHPLC+ system coupled to a QExactive Orbitrap mass spectrometer equipped with a heated electrospray ionization (H-ESI) source probe (M/s Thermo Fischer Scientific, Waltham, MA, USA). A SeQuant ZIC-pHILIC (2.1 × 100 mm, 5-μm particles) HILIC phase analytical column from Merck (M/s Merck KGaA, Darmstadt, Germany) was used as a chromatographic separation column. Gradient elution was carried out with a flow rate of 0.100 mL/min using 20 mM ammonium carbonate, adjusted to pH 9.4 with ammonium solution (25%) as mobile phase A and acetonitrile as mobile phase B. The gradient elution was initiated from 20% mobile phase A and 80% of mobile phase B and maintained for 2 min. After that, 20% mobile phase A was gradually increased up to 80% until 17 min, then mobile phase A was decreased from 80% to 20% in 17.1 min and is maintained up to 24 min. The column oven and auto-sampler temperatures were set to 40 ± 3°C and 5 ± 3°C, respectively. MS equipped with a heated electrospray ionization (H-ESI) source using polarity switching and the following settings: resolution of 35,000, the spray voltages: 4250 V for positive and 3250 V for negative mode, the sheath gas: 25 arbitrary units (AU), and the auxiliary gas: 15 AU, sweep gas flow 0, Capillary temperature: 275°C, S-lens RF level: 50:0. Instrument control was operated with the Xcalibur 4.1.31.9 software (M/s Thermo Fischer Scientific, Waltham, MA, USA). The peaks for metabolite were confirmed using Mass spectrometry metabolite library kit MSMLS-1EA (Ms Sigma Aldrich supplied by IROA Technologies). Peak integration was done with the TraceFinder 4.1 software (M/s Thermo Fischer Scientific, Waltham, MA, USA). The area peak data was exported as an Excel file for further analysis. Data quality was monitored throughout the run using pooled healthy human serum as Quality Control (QC) processed and extracted in the same way as unknown samples and interspersed throughout the run as every 10th sample. After integrating QC data with TraceFinder 4.1, each detected metabolite was checked and %RSD was calculated, and the acceptance limit was set ≤20%. Blank samples for carryover were injected after every fifth unknown samples to monitor the metabolites’ carryover effect and calculated against the mean QC area, and the acceptance % carryover limit was set ≤20% for each
metabolite. Background noise blank (first solvent blank of the run) was injected, and % background noise was calculated against the mean QC area, and the acceptance % background noise limit was set \( \leq 20\% \) for each metabolite.

**Cytokine array analysis**

The cell culture supernatants from mock-infected and hCoV-19-S15 strain infected CALU3 cells were collected at indicated time points (0, 3, 6, 12, 24, and 48 h post-infection (hpi) and subjected to centrifugation for 5 min at 14,000 rpm. Cytokines were analyzed using Proteome Profiler Human Cytokine Array Kit (R&D Systems) according to the manufacturer’s instructions. The membranes were exposed to X-ray films, scanned, and analyzed using ImageJ software (NIH). The fold change was calculated in comparison to the mock-infected sample.

**Western blot analysis**

Protein samples were run on pre-cast NuPAGE Bis-Tris gels (Invitrogen) with 1x MOPS buffer (Invitrogen) and transferred on nitrocellulose membranes using the iBlot2 Gel Transfer Device (Invitrogen). Membranes were washed in Tris-Buffered Saline with 0.1% Tween-X100 (TBS-T) and blocked with TBS-T containing 5% BSA (BSA, Sigma-Aldrich). Membranes were incubated with primary antibodies at 4°C overnight. The following primary antibodies were used; anti-β-Actin (1:5000; cat#6276; Abcam), anti-OAS1 (1:1000; cat#14498; Cell Signaling Technology), anti- ISG15 (1:1000; cat#2734S; Cell Signaling Technology), anti-TRIM5α (1:1000; cat#14326; Cell Signaling Technology), anti-RNase-L (1:1000; cat#27281; Cell Signaling Technology), anti-MX1 (1:1000; cat#37849; Cell Signaling Technology), anti-TYKi (CMPK2) (1:1000; cat#NB1-80653; Novus Biologicals), anti-p53 (1:1000; cat# 9282; Cell Signaling Technology), anti-phospho p53 (Ser15) (1:1000; cat#82530; Cell Signaling Technology), anti-phospho γH2AX (Ser139) (1:1000; cat#2577; Cell Signaling Technology), anti-phospho TBK1 (Ser172) (1:1000; cat#5483; Cell Signaling Technology), anti-phospho IRF3 (Ser396) (1:1000; cat#29047; Cell Signaling Technology), anti-phospho JNK (Thr183/Tyr185) (1:1000; cat#4668; Cell Signaling Technology), anti-phospho ERK1/2 (Thr202/Tyr204) (1:1000; cat#4370; Cell Signaling Technology), anti-phospho p38 (Thr180/Tyr182) (1:1000; cat#4511; Cell Signaling Technology), anti-phospho STAT1 (Ser727) (1:1000; cat#8826; Cell Signaling Technology), anti-phospho STAT3 (Tyr705) (1:1000; cat#8159; Cell Signaling Technology), anti-phospho STAT5 (Ser91) (1:1000; cat#5220; Cell Signaling Technology), anti-phospho YAP1 (Ser61) (1:1000; kind gift from Dr. Wenqi Wang, University of California, Irvine). Membranes were washed in TBS-T and incubated with secondary antibodies (HRP-conjugated, DAKO) for 1 h at room temperature in TBS-T containing 5% milk or BSA. The blots were developed with Super-Signal West Femto Substrate (Thermo Scientific) and captured with LI-COR Odyssey system (LI-COR Biosciences, Lincoln, NE, USA).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

The transcriptome FPKM data was subjected to differential analysis. Differentials at each time point were determined using a p-value cut-off of \( < 0.01 \) and log2(fold-change) cut-off of \( \pm 1.5 \). Protein abundances and phosphosite abundances across multiple replicates were subjected to quantile normalization and differential expression using limma (v3.44.3) in R (v4.0.2) (https://www.r-project.org/). Log2 fold changes and p-values were calculated using the proDA (v1.2.0) package for R. Differentials at each time point were determined using a p-value cut-off of \( < 0.05 \) and log2(fold-change) cut-off of \( \pm 1.5 \). For the Acetylome data, abundance ratios obtained from Proteome Discoverer were considered for further analysis. The proteomics and phosphoproteomics datasets generated in the current study were compared with corresponding datasets from Thorne et al.,\(^\text{27}\) Hekman et al.,\(^\text{31}\) Stukalov et al.,\(^\text{29}\) and Grossegesse et al.\(^\text{13}\) Gene ontology and Pathway analysis for transcriptome total proteome, phosphoproteome and acetylome data were carried out using enrichR (v3.0) R package. The enrichment databases consisted of “GO_Biological_Process_2015”, “GO Cellular_Component_2015”, and “Reactome_2015” and significant enrichment used a p-value cut-off of 0.05. A list of ISGs was compiled based on previous literature.\(^\text{27,161}\) The gene sets pertaining to cytokines, chemokines, Hippo signaling, regulation of Hippo signaling, DNA damage response, DNA repair, protein ubiquitination, Regulation of protein mono and polyubiquitination, Alternative splicing by spliceosome, and Regulation of mRNA splicing via spliceosome were obtained from MSigDB (v7.5.1), and comparisons were carried out. The differentials from the phosphoproteome data were subjected to gene set enrichment analysis (GSEA) against the PTM signatures database (PTMsigDB),\(^\text{162}\) which consists of modification site-specific signatures of perturbations kinase activities, and signaling pathways curated from the literature.
Peak areas for the assayed metabolites were obtained for the specified time points and replicates for the metabolomics data. Fold changes were calculated by dividing the peak area for each time point by the peak area for the unstimulated sample and carrying out the log transformation to the base 2. Replicate values for each time-point were averaged. Metabolites with log2 fold-change values $\geq 1$ were considered to be increased, whereas those with log2 fold-change values $\leq -1$ were considered to be decreased compared to unstimulated samples. The metabolites increased at each time point and were subjected to metabolite set enrichment analysis (MSEA). Overrepresentation-based MSEA was carried out against the KEGG database using Metaboanalyst 5.0 (https://www.metaboanalyst.ca/). The individual MSEA results were joined, and the p-value was plotted as a heatmap in R using the pheatmap package (v1.0.12). 2D structures of key metabolites were fetched manually from ChemSpider (http://www.chemspider.com/).

**Kinase motif prediction**

Kinase motifs of phosphopeptides from SARS-CoV-2 proteins were predicted using NetPhos 3.1 using the SARS-CoV-2 protein fasta file downloaded from Uniprot, which was also used for the proteomics data analysis. Only kinases with a score above 0.5 were considered positive hits.

**Structural analysis of phosphorylation sites**

Molecular graphics and analyses were performed with UCSF ChimeraX. Experimental models were used for ORF7a (PDB ID 6w37) (https://doi.org/10.2210/pdb6w37/pdb), ORF8 (PDB ID 7jx6) (https://doi.org/10.2210/pdb7jx6/pdb), ORF9b (PDB ID 7kdc). Models for full-length ORF3a, ORF6, M, N, Rep1a residues 1-180 (Nsp1) and residues 2483-2667 (Nsp3) were obtained using TrRosetta through the Robetta server. For visualization, regions of Robetta models present in the experimental structures of ORF3a (PDB ID 7kj7), N NTD (PDB ID 6vyo) (10.2210/PDB6VYO/PDB) and CTD (PDB ID 6wzo), Rep1a Nsp1 NTD (PDB ID 7k7p) and CTD (PDB ID 7jqb) were hidden in the illustrations and replaced by the experimental models. Structural models of SARS-CoV-2 proteins were visualized as cartoon representations and surfaces were colored by electrostatic potential.